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Abstract 
 
Proper folding of proteins into native structure is essential for their biological activity. 
Proteins achieve native state with the help of several cellular regulatory mechanisms 
assisted by molecular chaperones. Alteration in these regulatory mechanisms can lead to 
protein misfolding. Also failure to dispose of the misfolded protein load causes 
accumulation of misfolded proteins and toxicity. The accumulated protein in some cases 
may self-assemble into stable, β-sheet rich oligomers and aggregates known as amyloid 
fibrils. Amyloid aggregation has been implicated to cause several diseases such as 
Alzheimer’s, Parkinson’s and renal amyloidosis etc. 
In this study, amyloid-like aggregation of human proteins Semenogelin-1 (Sg1), and 
Serum albumin (HSA) have been investigated. Aggregation of human Sg1 protein is 
observed in Senile seminal vesicle amyloidosis (SSVA) disorder. HSA is the most 
abundant protein in blood plasma and has been shown to aggregate in vitro similar to 
amyloid proteins. Key unanswered questions that have been investigated here are, 
whether Sg1 full length protein can form amyloid aggregates in vitro and whether HSA 
aggregates exhibit true amyloid properties. We succeeded in obtaining aggregates of Sg1 
and Sg1 (1-159), which manifested amyloid-like binding to Thioflavin-T and Congo red 
dyes and also followed lag-dependent sigmoidal growth pattern and beta-sheet rich 
conformation, as established previously for several amyloids. Furthermore, these 
aggregates also exhibited amyloid-like stabilities to ionic detergents: SDS and Sarkosyl. 
In addition, dynamic light scattering (DLS) results estimated presence of  > 400 nm size 
particles in both Sg1 and Sg1(1-159) aggregates and exhibited amyloid-like fibrillary 
morphology in TEM. Notably, Zn2+ which is known to bind to Sg1 in vivo was found to 
partially inhibit amyloid aggregation of Sg1 and Sg1 (1-159) in vitro.  
Here, it is also observed that HSA aggregates display true amyloid characteristics of self-
seeding and detergent stability. This was further supported by fibrillar morphologies as 
observed by TEM and AFM. Furthermore, HSA homodimer has been obtained without 
the use of a chemical cross-linker, which being non-immunogenic, can find potential 
therapeutic preference over conventional HSA dimers obtained via chemical cross-
linking. Notably, HSA dimers retain the amyloidogenic properties similar to that of the 
HSA monomers, thus suggesting need for therapeutic precautions. In conclusion, this 
thesis explores the amyloidogenic properties of full length Sg1 and also provides new 
insights into amyloid-like aggregation of HSA monomer and dimer.  
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Chapter I 
  
Introduction to protein 
misfolding, amyloid aggregation and amyloidoses 
 
 
 
1.1 Protein folding and misfolding 
Proper folding of proteins into native structure is essential for their function and solubility 
[1]. The biological function of cells depends on the correct folding of several proteins. 
The information required to fold a protein into its functional conformation resides in its 
amino acid sequence. Transition between different folded states of protein is regulated by 
cellular environment and factors such as molecular chaperones. Generally proteins fold 
properly into their native conformation and, any misfolding during the process is 
corrected by chaperone proteins. But if this cellular quality control mechanism fails, it 
can result in aggregation and accumulation of misfolded protein deposits (Figure 1). This 
may lead to the development of protein misfolding disorders such as amyloid and prion 
diseases [1]. Also alterations in a protein’s primary amino acid sequence due to mutations 
or changes in the cellular homeostasis, can lead to misfolding of proteins that 
compromises their function. Additionally, misfolded proteins can accumulate in vivo into 
ordered beta sheet-rich aggregates termed amyloid that cause toxicity and disease [1,2].  
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Figure 1. Protein misfolding: the various states accessible to a protein molecule 
(adapted from Dobson,2003, Nature) [1] 
 
1.2 Amyloid aggregation 
Amyloid fibrils are highly organized, insoluble, thread-like aggregates of misfolded 
protein and are associated with various diseases.  These are approximately 75-100 Å in 
diameter. They have characteristic cross β-sheet structure, revealed by X-ray diffraction 
studies, where the β-sheets are parallel to the axis of the fibril with their strands 
perpendicular to this axis (Figure 2). Amyloid deposits exhibit characteristic apple green 
birefringence when stained with Congo red dye and viewed under polarized light, they 
also exhibit enhanced fluorescence on binding with Thioflavin-T [3,4]. Amyloid 
aggregates show unusual stabilities against denaturants (such as urea and ionic 
detergents) at room temperature, also partial resistance to proteinase-K digestion  and can 
self-seed and coax the non-amyloid forms of their protein monomers, also into amyloid 
aggregated conformation [5,6]. 
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(adapted from Nelson et al. 2005, Greenwald, 2010) [3,4] 
 
Thioflavin-T (ThT), a cationic benzothiazole dye, is widely used for the detection of 
amyloid aggregates both in solution and in tissue. Upon binding to amyloid fibrils, this 
dye exhibits an enhanced fluorescence with an emission maximum around 482 nm and a 
new absorption peak at 450 nm (Figure 3) [7]. Although, the specificity of ThT and Congo 
red dyes for amyloid detection has been debated, these continue to be preliminary probes 
for amyloid aggregation [8,9].  
 
Figure 3. Characteristic increase in Thioflavin-T fluorescence upon binding to amyloid    
fibrils [7] 
Amyloid aggregation follows lag dependent sigmoidal kinetics of formation [5]. Starting 
with a slow lag phase during which seed (or nucleus) is formed followed by elongation 
and then saturation phase therefore also referred to as nucleation dependent 
polymerization process (Figure 4). The rate of growth of amyloid fibres is increased by 
Figure 2. Cross β structure of peptide from the amyloid domain of the yeast prion Sup35p 
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the presence of pre-formed ordered aggregates which act as seed, in a process referred to 
as seeding [5]. Seeding ability of aggregates serve as a measure to distinguish ordered 
amyloid structures from randomly misfolded amorphous aggregates. 
The seeds act as a starting material or template for the assembly and growth of amyloid 
fibers. This also acts as a basis for the spread of amyloid deposits in tissues and from one 
organ to another in case of systemic amyloidosis. Amyloid aggregation shows sigmoidal 
growth curve with three phases:  
 a) Initial lag phase, during which oligomer protein “seed” or nucleus is formed  
 b) Log phase also called as exponential phase or polymerization phase, wherein seeds 
recruit the monomeric protein molecules in exponential manner.  
 c) Stationary phase, when amyloid is formed completely with no further increase in its 
fibrillization process.  
Seeding affects the kinetics by decreasing the lag phase and thus over all time to form the 
amyloid.  
 
Figure 4. Nucleation dependent amyloid growth [5,10] 
 
1.3 Pathology of amyloidoses  
Amyloidosis is the pathological state which involves extracellular deposition of  protease 
resistant protein fibrils in tissues and organs as a result of the transition of soluble protein 
to insoluble form with ordered structure [11]. A wide range of human pathologies are 
associated with aggregation of misfolded proteins. Although, they exhibit clinically 
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distinct conditions (Figure 5). At present, more than 30 different types of amyloidoses 
have been defined [12]. 
Several amyloid associated debilitating human diseases have been identified such as 
Alzheimer’s disease, Prion disease, Huntington’s disease & renal amyloidosis where the 
Aβ-42 peptide, PrPC protein, mutant huntingtin protein & human lysozyme, are 
respectively found to be amyloid aggregated and deposited (Figure 5). 
 
 
 
Figure 5. Amyloid aggregates in neurodegenerative diseases 
(adapted from Soto.C et al, Nat Rev Neurosci, 2003) [13] 
 
Amyloidoses can be systemic or localized (Table 1). Localized amyloidoses are thought 
to be amyloid deposits derived from the proteins synthesized at the cells located in the 
region of accumulation. Semenogelin-1 has been identified as the amyloid protein that 
accumulate in localized senile seminal vesicle amyloidosis (SSVA) [12,14]. SSVA is 
mostly asymptomatic while other amyloidoses can be neurodegenerative or non-
neuropathic. 
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Table 1.  Examples of amyloid diseases and associated aggregating protein in humans 
    (adapted and modified from Chiti & Dobson, 2006; Sipe et al 2010) [2,12] 
Amyloid disease Aggregating protein 
a) Non-neuropathic amyloidosis 
Systemic 
Primary systemic amyloidosis Immunoglobulin light chain 
Ig-heavy chain associated amyloidosis Immunoglobin heavy chain 
Hemodialysis-related amyloidosis β2-microglobulin 
Senile systemic amyloidosis Transthyretin 
Secondary (reactive) systemic 
amyloidosis 
Serum amyloid A protein 
Hereditary  systemic  ApoAI amyloidosis Apolipoprotein AI 
Sporadic  systemic  ApoAIV amyloidosis Apolipoprotein AIV 
Familial hereditary amyloidosis Gelsolin 
Hereditary lysozyme amyloidosis   Lysozyme 
Hereditary renal amyloidosis Fibrinogen α chain 
Localized 
Spongiform encephalopathies Aβ precursor protein (PrP) 
Medullary carcinoma of the thyroid (Pro)calcitonin 
Diabetes mellitus Islet amyloid polypeptide 
Atrial amyloidosis Atrial natriuretic factor 
Injection-localized amyloidosis Insulin 
Pulmonary alveolar proteinosis Lung surfactant protein C 
Odontogenic tumors 
Odontogenic  ameloblast-associated 
protein 
Seminal vesicle amyloid Semenogelin I 
b) Neurodegenerative amyloidosis 
Alzheimer’s disease Amyloid β peptide 
Spongiform encephalopathies Prion protein (PrP) 
Parkinson’s disease  α-synuclein 
Huntington’s disease Huntingtin  with poly Q expansion 
Amyotrophic lateral sclerosis Superoxide dismutatse 1 
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1.4 Naturally occurring amyloids 
Besides pathological amyloid some functional amyloids have also been identified in both 
eukaryotes and prokaryotes where they can have beneficial roles [2]. 
Amyloid structures can sometimes have beneficial function rather than disease-associated 
properties in living systems under particular environmental conditions. For example E. 
coli have amyloid forming protein curlin helping it to colonize inert surfaces and mediate 
binding to host proteins. The filamentous bacterium Streptomyces coelicolor secrete 
amyloid forming protein chaplins that lower the water surface tension and allow the 
development of aerial hyphae [2]. Numerous other proteins, including some human 
proteins, which are not associated with any disease, can also form amyloid-like 
aggregates in vivo (e.g. mammalian Pmel17 protein; yeast Sup35 & Cyc8 proteins etc.) 
or even in vitro (e.g. human serum albumin, bovine serum albumin, hen egg white 
lysozyme, endocrine hormones such as ACTH & Oxytocin etc.) [2,15-17]. Non-disease 
associated amyloid forming proteins have been used as a model system to understand: 
a) General mechanism of amyloid formation [18]; b) Amyloid cross-seeding such as 
study of crossing of species barrier by prions [19]; c) Potential application as structural 
nano-materials [20]; d) The propagation of amyloid and prion e.g. sup 35 is used to study 
the infection mechanism of prion [21]; e) Potential application as drug delivery agent; 
e.g. Insulin amyloid aggregates as potential sustained insulin delivery tool for diabetes 
treatment [22].  
Prions are infectious proteins capable of propagating protein misfolding and aggregation 
[23]. They cause fatal neurodegenerative diseases. Prion diseases are characterized by 
accumulation of the misfolded, protease-resistant prion protein termed PrPSc. When a 
prion enters a healthy organism, it induces existing, properly folded proteins to convert 
into the disease-associated, prion form; the prion acts as a seed to bind with normal, 
cellular prion protein of host denoted as PrPC catalyzing its conversion into the misfolded, 
pathogenic form PrPSc  thus mediate prion transmission [24]. The molecular mechanism 
underlying prion propagation is strikingly similar to the mechanism of amyloid formation. 
Prion proteins are also found in yeast, which has been useful to understand mammalian 
prions. 
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Yeast prions are infectious protein that behaves as a non-Mendelian genetic element and 
transmits biological information in the absence of nucleic acid [25]. The well-known 
prion proteins in yeast are Sup35, Rnq1, Ure2, Cyc8 and HET-S, which leads to the 
corresponding prion state [PSI+], [PIN+],[URE3], [OCT+] and [Het-s] respectively 
[26,27].  Most of the yeast prions are rich in glutamine/asparagine residues. Prion proteins 
can adopt different stably propagating conformations which gives rise to prion variants 
in vivo [28].  All known prion diseases, collectively called transmissible spongiform 
encephalopathies (TSEs). The human prion disease variant Creutzfeldt-Jakob disease, is 
believed to be caused by a prion which typically infects cattle, causing Bovine 
spongiform encephalopathy and is transmitted through infected meat [24]. 
 
1.5 Amyloid forming protein: Semenogelin-1 
Senile seminal vesicle amyloidosis (SSVA) is a form of localized amyloidosis affecting 
male reproductive system. SSVA manifestation could remain asymptomatic or display as 
hematospermia and supra pubic pain which may be frequently mis-diagnosed as 
carcinoma [29,30].  
 
 
Figure 6. Congo red stained sections of seminal vesicle showing Sg1 aggregates deposits  
(A) under bright field (B) polarized light (adapted from Linke et al, 2005) [14] 
 
The occurrence of SSVA increases with progressing age and it is found in over 20 % of 
men above 75 years of age [31]. The protein Semenogelin-1 (Sg1) has been identified to 
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be the major component of protein deposits in SSVA (Figure 6) [12,14]. Sg1 is also the 
predominant protein required for formation of human semen coagulum, the gel matrix 
that encases spermatozoa [32]. This form of amyloidosis is designated as ASemI [12,14]. 
Semenogelin-1 is the most abundant protein of human semen coagulum. It is synthesized 
and secreted by the seminal vesicle and are involved in formation of gel matrix that 
encases spermatozoa just after ejaculation [32]. 
Human semen coagulum contains semenogelin-1 (Sg1) and semenogelin-2 (Sg2), Sg1 is 
the predominant form with molecular mass of 52 kDa while less abundant protein Sg2 
has two different forms of 70 kDa and 76 kDa. The precursor for semenogelin consists of 
462 amino acid residues which after cleavage of 23 residue signal peptide yields mature 
functional protein of 439 amino acids [33]. Alternative splicing gives rise to two different 
isoforms of semenogelin-1 (Figure 7).  
 
 
Figure 7. Schematics of Isoform 1 and Isoform 2 of semenogelin-1 protein 
 
Semenogelin has abundance of glutamine, asparagine and lysine amino acid residues 
analogous to yeast prion proteins which can form amyloid aggregates. The semenogelins 
exhibit 78 % similarity in their primary structure, and are composed of repetitive units 
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[34]. The only post translational modification is the presence of a pyroglutamine residue 
at its N-terminus [32,35]. 
 
Table 2. Characteristics of  Semenogelin-1 gene and protein [33]  
 Characteristics Properties 
 
Gene 
Open reading frame 1389 nucleotides 
Exon structure 
exon I: signal peptide 
exon II: mature protein 
exon III: 3% non-translated 
region 
Chromosomal  localization 20 q12–13.1 
 
 
 
 
 
 
 
Protein 
Molecular weight 49620–49958 Da 
Amino acid residues 
signal peptide: 23 
mature protein: 439 
total: 462 
Cysteine residue 1 (at residue 216) 
Internal repeats six repeats of 60 amino acid units 
Isoelectric point 9.5 
Similarity with Sg2 
 
nucleic acid 89% (within 
exons) 
protein 78% 
Posttranslational 
modification 
N-terminal 
pyroglutamination 
Sperm motility inhibitor 
(SPMI) domain 85-106 
 
Semenogelin undergoes proteolytic processing by protease, prostate specific antigen 
(PSA) [36]. This mediates liquefaction of the gel aiding in progressive release of motile 
spermatozoa. Semen contains a high concentration of Zn2+ ions, which is known to inhibit 
the protease activity of PSA. Semenogelins bind Zn2+  ions  with high affinity, thus 
regulate the enzymatic activity of PSA by bringing down the level of free Zn2+ ions low 
enough to block the inhibition and thereby enable activation of PSA [37]. Cleavage of the 
semenogelins by PSA during liquefaction is important for fertilization as semen with slow 
liquefaction rate leads to infertility. In addition to having coagulum forming functions the 
semenogelins have been reported to be involved in other functions like activation of 
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sperm hyaluronidase which facilitates fertilization, serve as substrates for 
transglutaminase [38], affect sperm motility [35], possess anti-microbial activity derived 
from peptides generated by fragmentation of the semenogelins which provides protection 
for the spermatozoa in the female reproductive tract [39,40], and exhibit amyloid 
properties [14]. 
Besides being expressed in seminal vesicle, studies have shown that semenogelin-1 and 
semenogelin-2 are also expressed in salivary glands, trachea, kidney, pancreas, prostate, 
but at much lower levels and retinal pigment epithelial cells (which is known to contain 
high levels of zinc) this indicates that these proteins are involved in functions beyond 
reproduction and fertility [41,42]. A wider role for semenogelin-1 may be suggested by 
observations that, it has been found to be expressed in leukaemia, small cell lung 
carcinoma, and prostate cancer. Recently Sg1 have been reported to be expressed in renal 
cell carcinoma, suggesting Sg1 expression as a marker for human malignancies [43-46]. 
It has been reported previously that naturally occurring fragments of prostatic acid 
phosphatase (PAP), an abundant protein secreted into semen from the prostate form 
amyloid fibrils consisting of amino acid residues 248–286. These fibrils, termed Semen-
derived Enhancer of Virus Infection (SEVI), promote attachment of HIV virions to target 
cells, thereby enhancing HIV infectivity [47].  
Like SEVI, certain peptide fragments of Sg1 [Sg1 (45-107), Sg1 (68-107), Sg1 (86-107) 
and Sg1 (38-48)] have been reported to form amyloid aggregates in vitro and have been 
shown to greatly enhance HIV infection in cell cultures (Figure 8). Data suggest that the 
enhancement of HIV infectivity may be due to the cationic surfaces which may facilitate 
HIV virion attachment and entry [48-50]. Very recently, the interaction of fibronectin 
with semen amyloids (such as Sg1 amyloid and SEVI) has also been reported to facilitate 
enhancement of HIV infection [51]. Therefore, Sg1 may be used as a model amyloid 
protein. Also a small peptide Sg1 (38-48) was reported to be capable of self-assembling 
into hydrogel at neutral pH mostly pH 7.0 and pH 9.0, containing β-sheet rich fibrillar 
aggregates. The size of the formed aggregates by this peptide were reported to be in 
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micrometres as measured by dynamic light scattering [52]. However, the amyloid 
forming ability of Sg1 full length protein has not been established in vitro.  
Very recently, Hsp104 has been shown to be remodelled to antagonise against seminal 
amyloids like SEVI and Sg1. Thereby, acting as a strategy to reduce their ability to 
promote HIV infection [53]. 
 
 
Figure 8. Electron micrographs of fibrillar structures from Semenogelin-1 peptides 
Scale bars indicate 500 nm (adapted from Roan et al, 2011) [48,49] 
 
Semenogelin aggregates enhance HIV infectivity. During semen liquefaction, fragments 
released from the semenogelin proteins form amyloid fibrils that electrostatically attach 
to HIV virions and direct them to target cells (Figure 9). 
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Figure 9. Sg1 peptide amyloid facilitates HIV virion attachment and entry to cultured cells 
                (adapted from Roan, Warner C. Greene et al, 2011) [48] 
In SSVA disorder, Sg1 amyloid deposits in the sub-epithelium and lumen of seminal 
vesicles (Figure 6 & Figure 10). Thus, we expect that it is the full length Sg1 which would 
form amyloid aggregates in vivo, as it would not have, thus far, encountered the protease 
PSA. The fragmentation of Sg1 by PSA occurs after it is released out of the vesicles and 
mixed with prostatic fluid. Thus, amyloidogenicity of full length Sg1 needs to be 
examined to get a mechanistic insight into the development of SSVA. Also, examination 
of HIV infectivity in presence of full length Sg1 amyloid aggregates may be 
physiologically more relevant compared with the thus far obtained amyloid aggregates of 
Sg1 peptides which are generated only downstream post-ejaculation. Further, the formed 
amyloid aggregates can act as a target for inhibitor analysis with relevance to SSVA 
disease.  
Seminal vesicle amyloidosis incidence increases with age [31]. Seminal levels of certain 
constituents such as α-glucosidase, fructose, and zinc also decrease with age, however 
any correlation with SSVA is yet to be established [54,55]. The average reported seminal 
concentration of α-glucosidase is 2.74 mg/100mL, fructose is 272 mg/100mL and zinc is 
16.5 mg/100mL in healthy adults [56,57]. 
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        Figure 10. Congo red staining of seminal vesicle sections 
(A) Nodular amyloid deposits with sub-epithelial location in seminal 
vesicle on light microscopy (x40). (B) Amyloid deposits with apple green 
reflection on polarized light microscopy (x40) [29]             
      
These constituents play significant role in maintaining fertility. The level of α-glucosidase 
in seminal plasma reflects the functional state of the epididymis. The α-glucosidase levels 
are positively correlated with sperm count and motility. Fructose has been reported to be 
a source of energy for the motility of the gametes [58]. Zinc is secreted from prostate into 
seminal fluid and is required for the formation of semen coagulum by Sg1 thereby plays 
an important role in sperm release and motility [59]. Reducing levels of prostate zinc 
content with aging is associated with prostate diseases like prostate cancer and oxidative 
stress that can cause increased DNA damage [60]. By seeing the relationship among 
advanced age, decreased prostate zinc content and increased occurrence of associated 
diseases we hypothesize that it may affect Sg1 dependent senile seminal vesicle 
amyloidosis.  Zinc as well as other cations like Copper have been shown to have a 
significant effect on amyloid aggregation. Zn2+ and Cu2+ have been shown to inhibit Aβ42 
amyloid formation which is implicated in development of Alzheimer’s disease [61,62]. 
As semen contains high concentrations of Zn2+ ions in young individuals which decline 
with age and SSVA cases increase with age, we tested if Zn2+ affects the aggregation of 
Sg1. Thus, understanding the role of Zn2+ in relation to aging would help to understand 
SSVA amyloidosis. In addition to full length Sg1 a large Sg1 (1-159) fragment 
encompassing the reported amyloidogenic peptide regions of Sg1 was also recombinantly 
purified and tested for amyloid aggregation and effect of Zn2+ was assessed. The Sg1 (1-
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159) fragment is still relevant to SSVA as it has all the available binding sites for cellular 
factors like Zinc. The amyloid formed by this fragment can act as a target for inhibitor 
analysis against SSVA disorder. 
1.6 Human serum albumin: amyloidogenic protein 
Human serum albumin (HSA) is the most abundant protein in human blood plasma. HSA 
is an all α-helix, globular protein made of  a single peptide chain of 585 amino acid 
residues with one free sulfhydryl group (on Cysteine-34) and 17 intrachain disulfide 
bonds (Figure 11) [63]. HSA contains one tryptophan residue (Trp-214). The molecular 
weight of HSA is 67 kDa. 
 
Figure 11. Secondary structure of HSA molecule  
                   (adapted from Biswas.S. et al, 2015) [64] 
HSA has multiple physiological roles like: as a regulator for blood pH & osmotic pressure 
and as a macromolecular carrier for transport of nutrients, hormones, & several 
compounds such as fatty acids, amino acids, bile salts & metals [65-67].  HSA is 
considered as a safe and non-immunogenic drug carrier and as a versatile plasma 
expander, as its administration is found to be helpful in the treatment of severe 
hypoalbuminemia during burns, nephritic syndrome, chronic liver cirrhosis and 
hemorrhagic shocks [68]. In fact, dimerized HSA molecules are preferred over 
monomeric HSA as plasma expander & drug carrier due to increased circulatory life and 
alleviating effect on the edema associated with unwanted extravasation of the monomeric 
HSA [68,69].  Nitric oxide (NO) is emerging as an anti-oncogenic agent. It has been 
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shown to have potential use in cancer therapy [70]. HSA can be a suitable candidate for 
NO transport because NO binds to Cys-34 of HSA to form S-nitrosylated HSA. HSA is 
an efficient carrier of NO and good candidate as antitumor drug due to its ability to 
promote the uptake of drugs with specificity to tumour tissue. Also, the HSA dimer is 
expected to have enhanced accumulation in tumors because of its large molecular weight 
[68]. 
So far, HSA dimers for clinical applications are obtained by cross-linking of its free 
cysteine residues using chemical cross-linkers that can be potentially immunogenic [68]. 
Thus the need is to obtain disulfide-linked HSA dimers without any chemical cross-
linkers. Although, HSA monomer can misfold in vitro and aggregate with several 
properties expected of amyloid aggregates, however, key amyloid property of self-
seeding remains to be demonstrated. Also, whether HSA dimer, which finds clinical 
applications, can also form amyloid is unexplored. For a protein as functionally versatile 
as HSA, both in vivo as well as in clinical applications, formation of self-seeding stable 
amyloid aggregates can be potentially hazardous.  
HSA is found to form amyloid-like aggregates in vitro at physiological pH 7.4 and also 
at acidic pH but only at elevated temperatures (65°C), when present in aqueous solvents 
(Figure 12) [71]. HSA aggregation has been reported at physiological pH at lower 
temperatures also (25°C, 37°C) however in presence of organic solvent ethanol [72-74]. 
HSA aggregates display varying morphologies under different aggregation conditions, 
possibly due to formation of different structural intermediates during the  aggregation 
pathway  [71,72]. Unlike a typical amyloid aggregation trend, which follows a lag 
dependent sigmoidal kinetics, there is absence of any apparent lag period in HSA 
aggregation [5,72]. 
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Figure 12. Proposed model for amyloid aggregation pathway of HSA 
(adapted from Bhattacharya et al, 2011) [18] 
Although, HSA aggregates have previously been shown to conform to several amyloid 
aggregate-associated properties such as thioflavin-T (ThT) dye binding, Congo red 
binding, electron microscopy and atomic force microscopy etc.[72] certain important 
properties such as the self-seeding ability and detergent stability have not been established 
yet. Amyloid self-seeding is usually assayed in vitro and monitored as decrease in lag 
period of aggregation, suggesting acceleration of conversion of monomers to aggregates 
[10]. If HSA aggregates exhibited self-seeding at physiological conditions, any unwanted 
HSA amyloid contamination in samples used for therapeutics, could potentially seed the 
in vitro circulating HSA monomers into amyloid form, which would be hazardous.   
Here we first converted HSA into aggregates exhibiting amyloid-like ThT dye binding 
and then we examined if the aggregates display amyloid-like detergent stability. 
Furthermore, we examined self-seeding behaviour of HSA aggregates at sub-optimal 
aggregation temperature, in the view that few previous attempts at optimal aggregation 
 18 
 
 
conditions were inconclusive, possibly due to lack of a discernible lag period in 
aggregation [72,75]. Due to buried nature of the free cysteine-34 in HSA structure, HSA 
dimers employed for clinical applications have often been obtained using chemical cross-
linkers of cysteine, which may potentially be immunogenic [68]. Here we attempted 
homodimerizing HSA via disulfide linkage using denaturation in urea and hydrogen 
peroxide (H2O2) induced oxidation. We then examined if HSA homodimers retain the 
amyloidogenic properties similar to the HSA monomers.  
We tried to explore further into some unanswered questions through this study. We 
hypothesize that full length Sg1 is expected to aggregate in vivo in the seminal vesicles as it 
has not encountered PSA which is secreted by prostate further downstream. Thus we 
investigated whether full length Sg1 show amyloid aggregation in vitro as it would be helpful 
to understand SSVA. Also, all the known amyloid forming fragments of Sg1 are generated by 
PSA digestion. Therefore, we examined whether any larger fragment of Sg1 [here: Sg1 (1-
159)] containing amyloid core is able to show amyloid-like aggregation. 
Next, we examined new aspects of HSA aggregation and investigated whether HSA 
aggregates exhibit true amyloid-like characteristics particularly exploring key amyloid 
properties of amyloid like self-seeding ability and detergent stability. HSA dimer is preferred 
for medical applications, therefore, we also assessed the amyloidogenic properties of HSA 
homodimer.  
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Chapter II 
 
Recombinant expression, 
purification & characterization of human 
Semenogelin-1 (Sg1) and Sg1 (1-159) proteins 
 
2.1 Abstract 
In this chapter we successfully demonstrated cloning, expression and purification of 
recombinant Sg1 full length and Sg1 (1-159) using bacterial expression vector. A segment 
of Sg1 encoding 1-159 amino acid residues was PCR amplified from pReceiver-B01 
expression vector containing ORF for full length Sg1, and cloned into the same 
recombinant expression vector to code for an N-terminal 6xHis-tagged fusion protein 
under the control of T7 promoter to obtain pBKP-Sg1 (1-159). The obtained clone was 
verified by DNA sequencing. The recombinant plasmids pReceiver-B01-Sg1 or pBKP-
Sg1 (1-159) respectively encoding full length Sg1 or Sg1 (1-159) fragment, were 
transformed into E. coli BL21-AI cells. The proteins were expressed as N-terminal 6xHis-
tagged fusion proteins by induction with 1mM IPTG and 0.15% L- arabinose, which were 
subsequently purified under denaturing conditions (8 M urea) using Ni-NTA agarose 
affinity column chromatography. Homogeneity of the purified proteins were assessed by 
SDS-PAGE and their molecular weights were estimated by relative mobility plots of 
protein molecular weight standards. Identity of the protein was further confirmed by 
western blotting using anti-His antibody. Then, refolding of the purified Sg1 was 
examined by intrinsic Tryptophan (Trp) fluorescence. Trp fluorescence spectrum of Sg1 
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showed a blue shift in λmax from ~ 350 nm to ~345 nm on decreasing urea concentration 
from 8 M to 0.5 M urea. Upon complete removal of the urea by dialysis, further blue shift 
in λmax at 336 nm was observed thereby indicating presence of tryptophan in a relatively 
hydrophobic environment and suggesting structure induction. However, as tryptophan 
λmax is expected to be ~ 320nm if it is in a completely internalized hydrophobic micro-
environment, the Sg1 even in absence of any denaturant, is largely unstructured as 
reported earlier. Notably, both Sg1 full length and Sg1 (1-159) proteins were found to 
precipitate upon dialysis when carried out above pH 7.0, even in the presence of over 100 
mM NaCl, however, they remained soluble when dialyzed at pH 3.0 -4.0. This observed 
aggregation around and above physiological pH bears resemblance to aggregation of Sg1 
in seminal vesicles in the SSVA disorder as the reported pH in seminal vesicles is ~ 8.5. 
As Sg1 (1-159) contains the reported amyloid forming regions, it can be employed for 
studying aggregation behaviour. SSVA disorder involves aggregation and deposition of 
Sg1 amyloid aggregates. But so far it has not been established whether full length Sg1 
can form amyloid aggregates. We further characterized the purified proteins Sg1 and Sg1 
(1-159) and found that they are in their native conformation. These recombinant proteins 
were then utilized further for study of amyloid aggregation abilities as reported in next 
chapter. 
2.2 Introduction 
Originally, Linke & Westermark et al in the year 2005, isolated samples from patients 
and upon proteomics studies utilizing mass spectroscopy identified peptides 
corresponding to Sg1 amino acid sequence thereby suggesting role of Sg1 aggregation in 
Senile Seminal Vesicle Amyloidosis (SSVA) [14]. It has been reported that Sg1 protein 
has a non-globular structure and an increasing tendency towards random coil formation 
[76]. Many recent studies have reported the probable role of Sg1 as a cancer marker [43-
46]. Also certain peptide fragments of Sg1 [Sg1 (45-107), Sg1 (68-107), Sg1 (86-107) 
and Sg1 (38-48)] have been reported to form amyloid aggregates in vitro and have been 
shown to greatly enhance HIV infection to cell cultures [48-50]. So far amyloid 
aggregation of full length Sg1 has not been demonstrated in vitro. Recombinant full 
length Sg1 protein could be employed for examining amyloid aggregation properties to 
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get better insight into the development of SSVA disorder and further may also serve for 
amyloid inhibitor analysis. Therefore, with the objective to explore the amyloid forming 
ability of full length Sg1 and Sg1 (1-159), we attempted recombinant expression and 
purification of these proteins. This chapter presents the cloning, recombinant expression 
and purification of Sg1 full length and Sg1 (1-159) and describes the characterization of 
the purified proteins. 
 
Figure 13. Schematics of recombinant proteins, his-tagged Sg1 full length and a cloned out 
fragment Sg1 (1-159) encompassing the previously reported amyloidogenic 
peptide region of 45-107 amino acids.  
 
2.3 Results and Discussion 
SSVA disorder is associated with deposition of Sg1 amyloid aggregates in seminal 
vesicle. Sg1 protein has previously been extracted from human semen however, the 
extraction procedure is complex [77]. Although, bacterial expression system is not 
considered very suitable for expression of human proteins primarily due to incapability 
of proper post-translational modification, as no major post translational modifications like 
glycosylation have been reported for Sg1 in vivo therefore, expression and purification 
from E. coli system would be expected to yield native like Sg1 protein [33]. Thus, we 
attempted recombinant expression of Sg1 protein and its fragment Sg1 (1-159) in E. coli 
and purification using Ni-NTA affinity chromatography under denaturing conditions.  
Furthermore, to assess amyloidogenicity, a larger fragment of Sg1 (amino acids 1-159) 
containing the previously reported small amyloidogenic peptide regions was also 
recombinantly expressed and purified like Sg1 [48]. Expectedly, additional amino acid 
sequences in this fragment  compared with the small reported amyloidogenic peptides, 
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may interact with cellular factors (like Zn2+) and could be examined for any effect of 
cellular factors on Sg1 amyloid aggregation. 
 
2.3.1 Cloning of Sg1 (1-159) in a recombinant expression vector and expression of 
recombinant Sg1 and Sg1 (1-159) proteins 
A plasmid containing cDNA of SEMG1 ORF for encoding human semenogelin-1 cloned 
in pReceiver-B01 bacterial expression vector was procured from Gene Copoeia, USA 
(Cat. No.EX-Z2245-B01). A segment of Sg1 encoding 1-159 amino acid residues was 
PCR amplified from pReceiver-B01 using primers (Forward: 
5’GCCAGCTTCGAATCGAAGGTCGAATGAAGCCCAACATCATC 3’ and Reverse: 
5’GGTGGCGATGCGGCCGCCTATTAATATTGACTGGATATTCCCTTTC 3’) and 
cloned into the same recombinant expression vector in frame with 6x histidine encoding 
tag using BstBI and NotI restriction enzymes to obtain pBKP-Sg1(1-159). Plasmid maps 
of pRB01-Sg1 and pBKP-Sg1(1-159) are shown indicating unique (single cutter) 
restriction enzyme sites and ORF regions of interest (Figure 14). 
 
 
 
Figure 14. Plasmid maps of pRB01-Sg1 and pBKP-Sg1(1-159) 
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(A) The plasmid pRB01-Sg1 encodes the following protein sequence from Sg1 
MKPNIIFVLS LLLILEKQAA VMGQKGGSKG RLPSEFSQFP HGQKGQHYSG QKGKQQTESK 
GSFSIQYTYH VDANDHDQSR KSQQYDLNAL HKTTKSQRHL GGSQQLLHNK QEGRDHDKSK 
GHFHRVVIHH KGGKAHRGTQ NPSQDQGNSP SGKGISSQYS NTEERLWVHG LSKEQTSVSG  
AQKGRKQGGS QSSYVLQTEE LVANKQQRET KNSHQNKGHY QNVVEVREEH SSKVQSLCPA 
HQDKLQHGSK DIFSTQDELL VYNKNQHQTK NLNQDQQHGR KANKISYQSS STEERRLHYG 
ENGVQKDVSQ RSIYSQTEKL VAGKSQIQAP NPKQEPWHGE NAKGESGQST NREQDLLSHE  
QKGRHQHGSH GGLDIVIIEQ EDDSDRHLAQ HLNNDRNPLFT 
 
(B) The plasmid pBKP-Sg1 (1-159) encodes the following protein sequence from Sg1 
MKPNIIFVLS LLLILEKQAA VMGQKGGSKG RLPSEFSQFP HGQKGQHYSG QKGKQQTESK 
GSFSIQYTYH VDANDHDQSR KSQQYDLNAL HKTTKSQRHL GGSQQLLHNK QEGRDHDKSK 
GHFHRVVIHH KGGKAHRGTQ NPSQDQGNSP SGKGISSQY 
 
 
Figure 15. Plasmid construction of pBKP-Sg1(1-159) 
(A) PCR product pBKP-Sg1(1-159) obtained using pRB01-Sg1 as template. 
(B) pBKP-Sg1(1-159) correct clone confirmation by restriction enzyme 
digestion. Uncut experimental DNA from all three selected clones (indicated 
as clone 3, 5, 6) for screening has been used as control. DNA bands 
visualized under UV light in an ethidium bromide stained agarose gel. 
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2.3.2 Purification of recombinant Sg1 and Sg1 (1-159) by Ni-NTA affinity 
chromatography 
Recombinant proteins full length Sg1 (Sg1) or Sg1 (1-159) were purified under 
denaturing conditions to prevent any mis-aggregation by following the protocol as 
described in methods section (Figure 16).  
 
 
 
Figure 16. Ni-NTA affinity purification profile of recombinant proteins 
                  (A) Sg1 full length (B) Sg1 (1-159) protein 
Purification profile of the eluted proteins (A) Sg1 and (B) Sg1 
(1-159) was obtained by measuring absorbance of eluted 
fractions at 280 nm by using UV-visible spectrophotometer 
 
2.3.3 Assessment of homogeneity and molecular weight of recombinant Sg1 and 
Sg1 (1-159) proteins 
Eluted fractions of Sg1 and Sg1 (1-159) showing high A280nm were examined for 
homogeneity and molecular weight respectively by using 10 % or 15 % Sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) under reducing condition by the 
method of Laemmli [78]. The eluted proteins were found to be homogenous on SDS-
PAGE. As expected based on their amino acid sequence, molecular weights of the 
purified Sg1 and Sg1 (1-159) were found to be 49 kDa and 18 kDa respectively by SDS-
PAGE as estimated using molecular weight standards (Figure 17). 
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Figure 17. Homogeneities of the recombinant proteins assessed by SDS-PAGE 
 Fraction from Ni-NTA affinity chromatography purification of (A) Sg1 
full length or (C) Sg1 (1-159) fragment were assessed on 10 % and 15 % 
SDS-PAGE respectively. Pooled homogeneous fractions of (B) Sg1 and 
(D) Sg1 (1-159) fragment were examined alongside a molecular weight 
marker on 10 % and 15 % SDS-PAGE respectively. Molecular weights of 
Sg1 full length and Sg1 (1-159) fragment were respectively estimated to 
be 49 kDa and 18 kDa. 
 
2.3.3.1 Estimation of molecular weight by relative mobility plot 
The homogeneity of recombinant Sg1 and Sg1 (1-159) proteins were assessed by SDS-
PAGE. The experimental molecular weight was calculated by plotting relative mobility 
of different proteins of molecular weight marker (New England Biolabs Inc.; Catalogue 
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No. P7703S). By substituting the values of relative mobility 0.235 for Sg1 and 0.448 for 
Sg1 (1-159) in the following equations respectively as obtained from the above plots,  
y = -0.5686 x + 1.1968  
y = -0.5886 x + 1.1807  
Where, x = log (molecular weight, kDa) and y is relative mobility. 
The experimental molecular weight of Sg1 was estimated to be 49 kDa and that of Sg1 
(1-159) was 17.47 kDa (Figure 18). 
 
 
Figure 18. Estimation of mol. wt. of recombinant Sg1 and Sg1 (1-159) using relative 
mobility plot of mol. wt. standards from figures 17B & 17D 
Relative mobility of different proteins in molecular weight standards (from 
figure 17B & 17D) were plotted against log of their known molecular weights. 
These standard plots were used for estimation of mol. wt. of (A) Sg1 and (B) 
Sg1 (1-159) protein. 
 
2.3.4 Identification of His-tag in purified Sg1 by western blotting 
As per the fusion design the identity of the purified Sg1 protein was confirmed by probing 
the presence of N-terminal 6xHis-tag using anti-his antibody by western blotting [79]. 
The protein band stained by Coommassie was also identified by the anti-his antibody in 
the western blotting (Figure 19). This confirms presence of his-tag in the recombinant 
Sg1 protein. 
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Figure 19. Identification of his6-tag in the recombinantly purified full length        
Sg1 protein by anti-his antibody using western blotting 
Sg1 protein was electrophoresed on SDS-PAGE gel and transferred 
to PVDF membrane by elctroblotting. Sg1 protein band on the 
membrane was probed with anti-his antibody.  
 
2.3.5 Characterization of the recombinant Sg1 and Sg1 (1-159) proteins 
2.3.5.1 UV-visible absorbance spectroscopy 
Protein absorb light in the UV-visible region of the spectrum. Most proteins have high 
absorbance at ~ 280 nm which can be used for measuring concentration of proteins. 
Observed absorbance is due to the presence of aromatic amino acid residues such as 
tryptophan, tyrosine and phenylalanine [80].  
When Sg1 and Sg1 (1-159) were examined for absorbance in UV-visible 
spectrophotometer, protein like absorbance spectra were observed. Sg1 showed peak 
absorbance at 280 nm and Sg1 (1-159) showed maximum absorbance near 270 nm 
(Figure 20). 
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Figure 20. Absorbance spectra of purified recombinant proteins 
(A) Sg1 and (B) Sg1 (1-159) by UV-visible spectroscopy 
Absorbance spectra of 0.2 mg/ml protein (A) Sg1 or (B) Sg1 
(1-159) was recorded using UV-visible spectrophotometer. 
Spectra acquired after baseline correction. 
 
As per the amino acid sequence, Sg1 has 2 Trp and 13 Tyr residues whereas Sg1 (1-159) 
comprises of 0 Trp and 7 Tyr residues. The observed difference in the trend of absorbance 
spectra of Sg1 and Sg1 (1-159) may be due to difference in composition of aromatic 
amino acids. 
 
2.3.5.2 Estimation of molar extinction coefficient 
(i) Molar extinction coefficient of purified Sg1 full length 
The molar absorption coefficient of a peptide or protein is related to its tryptophan (W), 
tyrosine (Y) and cysteine (C) amino acid composition. This value is approximately equal 
to the weighted sum of the molar absorption coefficients of these three amino acids at 280 
nm. It is calculated by the following equation:  
 
εmolar = (nW×5690) + (nY×1280) + (nC×120) 
 
Semenogelin-1 has 2 tryptophan, 13 tyrosine and 1cysteine residues.  
Therefore,  
εmolar = (2×5690) + (13×1280) + (1×120)  
= 11380 + 16640 + 120 
= 28140  
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Also, the relation between εmolar and εpercent is given by the following equation:  
 
(εmolar) 10 = (εpercent) × (molecular weight of protein) 
 
Therefore,  
(28140) 10 = (εpercent) × 49000  
εpercent = 281400/49000  
εpercent (280 nm) = 5.74  
 
(ii) Molar extinction coefficient of purified Sg1 (1-159) 
Sg1 (1-159) has 0 tryptophan, 7 tyrosine and no cysteine residues.  
Therefore,  
εmolar = (0×5690) + (7×1280) + (0×120)  
= 8960  
Also, the relation between εmolar and εpercent is given by the following equation:  
 
(εmolar) 10 = (εpercent) × (molecular weight of protein) 
 
Therefore,  
(8960) 10 = (εpercent) × 18000  
εpercent = 8960/18000  
εpercent (280 nm) = 4.97 
Concentration of protein can be calculated using the following equation:  
 
(A280 /εpercent) 10 = concentration in mg/ml  
 
Protein concentrations were estimated using extinction coefficients of Sg1 full length 
(ε
1%
280 =6 (gm/100ml)
-1cm-1) and Sg1 (1-159) fragment (ε1%280 =4.9 (gm/100ml)
-1cm-1) that 
were average of values determined spectrophotometrically and from expasy protparam 
tool using their amino acid sequences [80,81].  
 
2.3.5.3 Intrinsic fluorescence of Sg1 protein 
Most of the intrinsic fluorescence emission of a protein is due to excitation of its 
tryptophan residues. Tryptophan (Trp) fluorescence spectrum of a protein can help to 
monitor the folded or unfolded state of a protein. In native state Trp are primarily in 
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hydrophobic environment (buried within the core of the protein) and have high 
fluorescence intensity and λmax value around 315 nm to 320 nm. In contrast in a 
hydrophilic environment (exposed to solvent) Trp fluorescence intensity decreases and 
λmax value is greater than 330 nm [82,83].  
As semenogelin-1 contains two Trp residues, we examined Trp fluorescence emission 
spectra and observed λmax at 350 nm indicating presence of Trp in hydrophilic 
environment. Comparing the intrinsic fluorescence emission intensity of the protein upon 
excitation at 292 nm (excites only Trp) vs the excitation at 280 nm (excites both Trp and 
Tyr), it is apparent that there is significantly large contribution from tyrosine residues. 
This is consistent with the presence of only 2 tryptophan vs. 13 tyrosine residues in Sg1 
protein (Figure 21). 
 
 
Figure 21. Intrinsic fluorescence emission spectra of Sg1 dialyzed at pH 7.4 
Trp fluorescence spectrum of Sg1 (solid line) recorded by excitation 
at 292 nm and Tyr & Trp fluorescence spectrum of Sg1 (dotted line) 
acquired by excitation at 280 nm. 
 
2.3.5.4 Refolding of the Sg1 protein purified under denaturing conditions 
2.3.5.4.1 Tryptophan fluorescence of Sg1 under different urea concentrations 
The recombinant Sg1 protein purified under denaturing conditions in presence of 8 M 
urea was diluted in 10 mM sodium phosphate buffer, pH 7.4 with decreasing urea 
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concentration from 8 M to 0.5 M urea, while keeping the protein concentration same 
(0.2 mg/ml). Tryptophan emission fluorescence spectrum was recorded after excitation 
at 292 nm by monitoring emission from 300 nm to 400 nm. The spectrum showed blue 
shift in emission wavelength maximum (λmax) from ~ 350 nm to ~345 nm on 
decreasing urea concentration from 8 M to 0.5 M urea (Figure 22). Whereas, for the 
dialyzed protein (0 M urea) further blue shift in λmax at 336 nm was observed. This 
suggests presence of tryptophan in relatively hydrophobic environment indicating 
structure induction after dialysis. However, as tryptophan λmax is expected to be less 
than 320 nm if it is in an internalized hydrophobic micro-environment, possibly Sg1 
even in absence of any denaturant has very little structure or largely unstructured, as 
reported earlier [76,82] .  
 
 
 Figure 22. Assessment of refolding of Sg1 by intrinsic tryptophan fluorescence 
 (A) Trp fluorescence spectrum of Sg1 at different urea concentrations, (B) 
Trp fluorescence spectrum of dialyzed Sg1in absence of urea, (C) Trp 
fluorescence emission λmax of Sg1 plot against different urea 
concentrations from 8 M to 0.5 M. 
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The purified protein showed structural features similar to as reported previously for 
Sg1 isolated from the human source, as assessed by intrinsic tryptophan fluorescence 
spectrometry [76]. 
 
2.3.5.4.2 Refolding of Sg1 assessed by Far-UV Circular dichroism 
Circular dichroism (CD) is a very useful technique for determination of the secondary 
structure and folding properties of proteins. In proteins, structures such as α-helix and β-
sheet are chiral thus absorb circularly polarized light. The absorption of this light acts as 
a measure of the degree of folding of the protein. CD spectroscopy can be employed for 
determining the folding state of proteins by measuring the change in far-UV absorption 
(190 nm to 260 nm) as a function of denaturant concentration [84,85]. 
CD spectra have earlier reported native Sg1 to be largely unstructured protein [76]. Far-
UV spectral features of Sg1 at pH 7.4 in presence of 8 M urea showed mostly random 
coil (Table 3). At the same pH, on decreasing urea concentration to 2 M, there is relative 
increase in mean residue ellipticity at 222 nm. Whereas, CD spectra of Sg1 at pH 7.4 in 
presence of 0.5 M urea comprises of strong negative ellipticities at 208 nm and 215 nm 
which relatively decreases at 222 nm indicating presence of secondary structure (Figure 
23). In 0 M urea, at pH 7.4 the protein comes out of solution so CD spectra could not be 
recorded. However, in 0 M urea when dialyzed at pH 3.0 the protein did not come of 
solution. At pH 3.0, far-UV CD spectrum of Sg1 exhibits negative ellipticity at 215 nm 
indicating presence of β-sheet secondary structure (Figure 23). The refolding studies in 
presence of decreasing urea concentrations by far-UV circular dichroism of Sg1, showed 
possibility that the structure contains both α-helix and β-sheet rich domains.  
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Figure 23. Refolding of Sg1 as assessed by far-UV CD spectra 
CD spectra of Sg1 purified under denaturing conditions at pH 7.4 
were recorded in presence of decreasing urea concentration (A) 8 M 
urea, (B) 2 M urea, (C) 0.5 M urea, (D) Sg1 dialysed at pH 3.0 (0 M 
urea). 
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Table 3. Secondary structure estimation of Sg1 under different urea concentrations 
Panels from 
Figure 23 
Sample 
 Secondary Structure* 
Helix 
(%) 
Beta 
(%) 
Turn 
(%) 
Random 
(%) 
A Sg1+8M Urea, pH 7.4 7.9 0 34.5 57.6 
B Sg1+2M Urea, pH 7.4 41 0 47 12 
C Sg1+0.5M Urea, pH 7.4 20.7 43.4 16 20 
D Sg1 dialyzed No Urea, pH 3.0 33.4 0 14.6 52 
 * Secondary structures were estimated using Yang’s reference [84]. 
2.3.6 Aggregation of Sg1 and Sg1 (1-159) fractions during dialysis  
The proteins Sg1 (49 kDa) and Sg1 (1-159) (18 kDa) purified in 8M urea were subjected 
to dialysis at 4 °C against 10 mM sodium phosphate buffer, pH 7.4 in presence of 10 mM 
β-mercaptoethanol, using dialysis membrane having molecular weight cut off 14 kDa and 
3.5 kDa respectively. Dialysis helps to remove imidazole, urea and any other small 
molecule impurities. Also β-mercaptoethanol prevents any unwanted disulphide bond 
formation. 
 
 
Figure 24. Protein precipitation during dialysis 
(A, C) Dialysis of purified Sg1 or Sg1 (1-159) in 10 mM sodium phosphate buffer 
at pH 7.4. (B, D) SDS-PAGE of undialysed and dialysed Sg1 or Sg1 (1-159) using 
10 % and 15 % resolving gel respectively. 
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Strikingly both the proteins exhibited precipitation during dialysis at pH 7.4 (Figure 24 A 
and 24 C). To find an appropriate pH at which the dialysis would keep the protein in 
solution, buffers from pH 3.0 to 10.5 were screened. Only the samples dialyzed at pH 3.0 
or pH 4.0 were found to have soluble protein. Whereas, protein was found to precipitate 
at pH 7.4 and also at pH 9.0. Precipitation was observed even in presence of 150 mM 
NaCl at alkaline pH. On SDS-PAGE analysis the precipitated protein was found to be 
homogeneous. The precipitated protein was centrifuged at 10,000 rpm and the pellet 
fraction was found to be composed of full length Sg1 while the supernatant had very little 
protein and only minute fragments (Figure 24 B). Knowing that this alkaline pH where 
recombinant Sg1 precipitates is similar to seminal vesicles where Sg1 is synthesized and 
secreted [57,86], the precipitates obtained at pH 9.0 were examined for amyloid-like 
aggregates as discussed in the following chapter. 
 
2.4 Materials and Method 
2.4.1 Materials 
Ni-NTA agarose was purchased from Qiagen (USA), Ampicillin, Urea, Guanidine 
hydrochloride, Sodium dodecyl sulfate (SDS), PMSF, Imidazole, Acrylamide, N, N-
methylene bis-acrylamide, Coommassie brilliant blue R-250, CDP-star 
chemiluminescent substrate and dialysis membrane were obtained from Sigma (Co. 
USA). Anti-his antibody, APP-conjugated secondary antibody and Polyvinylidine 
fluoride (PVDF) membrane were from GE Healthcare. Protease inhibitor cocktail 
(complete EDTA free) was from Roche Applied Science. Q5 high-fidelity DNA 
polymerase and restriction enzymes were purchased from New England Biolabs (UK), 
PCR primers were obtained from Imperial Life Sciences (India). Plasmid isolation 
miniprep kit was obtained from Qiagen (Germany). Sodium phosphate monobasic, 
Sodium phosphate dibasic, were of molecular biology grade and procured from HiMedia 
(India).  
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2.4.2 Cloning of Sg1 (1-159) and expression of recombinant Sg1 and Sg1 (1-159) 
proteins 
Cloning of Sg1 (1-159) and expression of recombinant Sg1 and Sg1 (1-159) proteins was 
carried out as follows. A plasmid containing cDNA of SEMG1 ORF for encoding human 
semenogelin-1 cloned in pReceiver-B01 bacterial expression vector was procured from 
Gene Copoeia, USA (Cat. No.EX-Z2245-B01). A segment of Sg1 encoding 1-159 amino 
acid residues was PCR amplified from pReceiver-B01 using primers (Forward: 
5’GCCAGCTTCGAATCGAAGGTCGAATGAAGCCCAACATCATC 3’ and Reverse: 
5’GGTGGCGATGCGGCCGCCTATTAATATTGACTGGATATTCCCTTTC 3’) and 
cloned into the same recombinant expression vector in frame with 6x histidine encoding 
tag using BstBI and NotI restriction enzymes to obtain pBKP-Sg1(1-159). The identity 
of pBKP-Sg1(1-159) clone was further verified by DNA Sequencing results. Standard 
protocol was used for the cloning [87]. The cloned plasmid was transferred into 
competent DH5α E. coli cells. The transformed DH5α cells were stored in -86 °C for 
maintaining the plasmid stock. Recombinant plasmids pReceiver-B01 or pBKP-Sg1 (1-
159) respectively encoding full length Sg1 (Sg1) or Sg1 (1-159) fragment were 
transformed into competent E. coli BL21-AI cells (Invitrogen) as per the 
recommendations of the manufacturer. The bacterial cells were selected on the LB-Amp 
selection media (LB agar + ampicillin at 50 μg/ml concentration). When the bacterial 
cells reached an optical density of 0.25 at 600 nm, 0.15% L-arabinose was added, and 
cells were further incubated for 45 min at 37 °C until they reach an optical density of 0.4 
at 600 nm. Overexpression was induced by 1 mM isopropyl β-D-thiogalactopyranoside 
(IPTG) for 3 hours at 37 °C with continuous agitation in orbital shaker at 200 rpm. The 
cells were then harvested by centrifugation at 6000 rpm at 4 °C. The cell pellets were 
stored at -86 °C for future use.  
2.4.2.1 Polymerase chain reaction (PCR) 
PCR reaction was set up in a 0.2 ml PCR tube, by mixing the DNA template, 
corresponding primers, a thermo resistant high-fidelity DNA polymerase (Q5 DNA 
polymerase), deoxyribonucleoside triphosphates (dNTP’s) and a buffer solution 
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providing an optimum chemical environment for the enzyme activity and stability. 
Composition of PCR mix is as shown in Table 4. 
 
Table 4. Reagents for PCR amplification of Sg1 (1-159) 
 
Reagents   Volume (μl) 
PCR-grade H2O 31 
Forward primer (100 μM) 1 
Reverse primer (100 μM) 1 
DNA Template (70 ng/μl) 5 
Q5 Buffer (5X) 10 
dNTP (10 mM) 1 
Q5 DNA Polymerase 1 
Total volume 50 
 
 
PCR reaction was carried out using PCR Thermal cycler from Applied Biosystems 
(Thermo Fisher scientific) under following conditions: 
Melting temperature (Tm) for the Forward primer is 56 °C and for the Reverse primer is 
58 °C 
PCR conditions: 
i. Initial activation at 98 °C for 30 sec. 
ii. Denaturation at 98 °C for 10 sec.  
iii. Annealing at 54 °C for 30 sec. Amplification cycles (35x) 
iv. Extension at 72 °C for 30 sec. 
v. Final extension at 72 °C for 2 min. 
The PCR products were purified using gel extraction kit (Qiagen). Purification of the PCR 
product was necessary to eliminate traces of the reagents that can interfere with 
subsequent applications. Samples were stored at –20 °C.  
2.4.2.2 Agarose gel electrophoresis for DNA 
0.8 % agarose was boiled in 1x TAE buffer (40 mM Tris, 20 mM Acetic acid, and 1mM 
EDTA.), then added with ethidium bromide and poured into an electrophoresis gel 
chamber from Bio-Rad. DNA samples were loaded in wells using final 1x gel loading 
dye (60 % glycerol, 0.015 % bromophenol blue and 0.06 M EDTA) and run at 80 V for 
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30 min. Fluorescence from DNA bands were visualized under UV source using G-box 
from Syngene. 
2.4.2.3 Restriction digestion and ligation 
Restriction digestion of the vector and PCR product were performed in accordance with 
the manufacturers specifications for respective restriction enzymes used in a final volume 
of 50 μl. 
For the preparation of the ligation mix, the volumes of the insert and the vector were 
calculated according to their concentrations. Ligation was carried out at a molar ratio of 
1:3 vector to insert which were mixed with 2 μl ligation buffer and 1μl T4 DNA ligase 
(NEB) to yield an end volume of 20 μl. The reaction was incubated at 16 °C for 14 hrs. 
Identity of pBKP-Sg1 (1-159) clone was verified by restriction enzyme digestion using 
following set of restriction enzymes as shown in Figure 15B: 
i. BsmI+ApaI as Rxn I 
ii. BsmI labelled as Rxn II, single cut within the insert  
iii. ApaI as Rxn IV 
iv. BstBI+BsrGI as RxnV, for Insert release. 
v. BsrGI as RxnVI 
Insert: 0.5 kb, Vector: 5.5 kb, Ligation product: 6.0 kb (6064bp)  
Uncut experimental DNA from all three selected clones (indicated as clone 3, 5, 6) for 
screening has been used as control in parallel with restriction enzyme digests of the clone. 
DNA marker was loaded in two different locations. 
2.4.2.4 Transformation of E. coli 
The competent cells used for the transformation procedures were DH5α and BL21-AI 
E.coli cells. The antibiotic Ampicillin was used at a final concentration of 50 μg/ml for 
positive selection of cells acquiring the plasmid of interest. To begin, 50 μl of the 
competent cell were thawed on ice, followed by addition of 5 μl of plasmid DNA. The 
tubes were then placed on ice for 30 min, then in 42°C water bath for exactly 30 seconds 
to allow the DNA transfer into cell. Following this heat shock, samples were returned to 
the ice for 10 min. Next, 750 μl of Luria-Bertani (LB) media was added to the tubes and 
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they were then incubated for 90 min at 37 °C. After incubation, cells were centrifuged at 
5000 rpm for 2 min. The pellet was then resuspended in 250 μl LB broth. 100 μl of the 
cell culture was plated on to LB-Amp-agar plates. Simultaneously, one additional plating 
was carried out following the same procedure but without plasmid DNA as a control and 
plates were incubated overnight at 37 °C. 
 
2.4.3 Ni-NTA affinity purification of recombinant Sg1 and Sg1 (1-159) proteins 
Recombinant proteins full length Sg1 or Sg1 (1-159) were purified under denaturing and 
reducing conditions to prevent any mis-aggregation by following a protocol previously 
described for Rnq1 yeast protein [10]. For this, firstly 25 ml Ni-NTA affinity resin 
(Qiagen) was packed in chromatography column (200 mm x 25 mm). Affinity of Ni-NTA 
for the histidine residues present in the N term 6x His tag of the target protein helps in its 
purification. Meanwhile the bacterial cells were lysed under denaturing conditions by 
sonication at 4°C with 10 ml lysis buffer (50 mM sodium phosphate buffer, pH 7.4, 8 M 
urea, 5 mM imidazole, 10 mM β-mercaptoethanol) containing protease inhibitor complex. 
Purification under denaturing conditions helps in preventing mis-aggregation of the 
amyloidogenic target protein. β -mercaptoethanol was added to all the buffers to prevent 
scrambled disulfide bond formation. Protease inhibitor was added to prevent proteolytic 
degradation of samples. Then, cell extract was precleared by centrifugation at 10,000 rpm 
for 10 mins at 4 °C. The pellet was discarded and the supernatant was used for 
purification.  
Meanwhile, the column was washed and equilibrated with the equilibration buffer (50 
mM sodium phosphate buffer, pH 7.4, 8 M Urea, 5 mM imidazole, 10 mM β-
mercaptoethanol). The precleared cell extract was loaded onto Ni-NTA agarose affinity 
column and purification was carried out under denaturing conditions. Unbound and non-
specifically bound proteins were washed with 200 ml wash buffer (50 mM sodium 
phosphate buffer, pH 7.4, 8 M Urea, 10 mM imidazole, 10 mM β-mercaptoethanol). 
Followed by elution of the his-tagged proteins using elution buffer (50 mM sodium 
phosphate buffer, pH 7.4, 8 M Urea, 250 mM imidazole, 10 mM β-mercaptoethanol) and 
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1 ml fractions were collected. The fractions with protein were identified by measuring 
A280 nm using the elution buffer as blank. 
2.4.4 Western blotting 
To confirm the identity of the purified Sg1 full length protein the presence of N-terminal 
6x His-tag was probed with anti-his antibody by western blotting [79]. For this Purified 
Sg1 (10 µg) was electrophoresed on SDS-PAGE and transferred to PVDF 
(Polyvinylidene fluoride) membrane by electro-blotting. PVDF membrane was blocked 
with blocking buffer (5 % Casein solution) overnight. Then the membrane was washed 
using phosphate buffered saline-Tween-20 (PBST) consisting of 137 mM NaCl, 2.7 mM 
KCl, 8.1 mM Na2HPO4 and 1.5 mM KH2PO4, pH 7.4, 0.05 % Tween-20 for 4 times x 30 
minutes. The membrane was then incubated with anti-his primary antibody (1:3000 
dilution) for 1hr. This allows binding of primary antibody to the 6x His-tag of Sg1. 
Unbound primary antibody was removed by washing with PBST for 4 times x 30 minutes. 
Then the membrane was incubated with Alkaline phosphatase (APP)-conjugated 
secondary antibody (1:8000 dilution) which binds to the primary antibody and again the 
membrane was washed with PBST for 4 times x 30 minutes to remove any unbound 
secondary antibody. Finally the blot was detected using CDP-Star as Chemiluminescent 
substrate for APP and photographed using G-Box (Gel documentation system from 
Syngene).  
2.4.5 Intrinsic fluorescence  
Intrinsic fluorescence of proteins arise because of the fluorescent properties of tryptophan 
and tyrosine residues. Intrinsic fluorescence can be used as a measure for assessment of 
refolding of purified proteins as fluorescence of these residues depend on their 
microenvironment and solvent conditions [83]. 
2.4.6 Refolding of Sg1 assessed by Circular dichroism 
Dialyzed Sg1 was incubated with decreasing concentration of urea 8 M, 2 M, 0.5 M in 10 
mM sodium phosphate buffer, pH 7.4 while keeping the protein concentration same (1.5 
mg/ml). The samples were examined for any change in secondary structure using Far-UV 
circular dichroism (CD) spectroscopy [85]. CD spectra were recorded using Jasco J-1500 
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spectropolarimeter in the wavelength range of 190-260 nm using cuvette of 1mm path 
length. Mean residue ellipticity [θ] was calculated using the following equation: 
[θ]= (θobs * MRW) / (10*c*l) 
Where, θobs, c, l and MRW represent the observed ellipticity in milli-degrees, protein 
concentration in mg/ml, path length of cuvette in cm, and mean residue weight taken as 
112 Da respectively. The spectra were corrected for baselines.  
2.4.7 Dialysis of Sg1 and Sg1 (1-159) purified in 8 M urea 
To find a buffer of appropriate pH which would keep the protein in solution, buffers of 
different pH ranging from 2.0 to 10.5 were screened. The buffers used for different pH 
were 0.5 M glycine-HCl (pH 2.0, 3.0), 0.5 M sodium acetate (pH 4.0, 5.0), 0.5 M sodium 
phosphate (pH 6.0, 7.4), 0.5 M tris-HCl (pH 8.4, 9.4), 0.5 M glycine-NaOH (pH 10.5). 
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Chapter III 
 
Amyloid-like in vitro 
aggregation of Sg1 and Sg1 (1-159) proteins 
 
3.1 Abstract  
Senile seminal vesicle amyloidosis (SSVA), that may manifest as hematospermia is 
associated with deposition of semenogelin-1 (Sg1) protein aggregates in seminal vesicles. 
Sg1 is the predominant protein that entraps spermatozoa which are freed upon 
fragmentation of Sg1 by the protease prostate specific antigen (PSA), post semen release. 
Certain small peptide fragments of Sg1 have been reported to form amyloid aggregates 
in vitro that can enhance HIV infectivity to cell cultures. However, the amyloid deposits 
in the seminal vesicles are expected to be that of the full length Sg1, as PSA is encountered 
downstream. So far, amyloid forming ability of full length Sg1 has not been established 
in vitro. Here, we examined the amyloidogenicity of full length Sg1 and a large fragment 
Sg1 (1-159), using recombinant proteins and tested if Zinc has any effect on their 
aggregation. Levels of Zinc, which is essential for health of male reproductive system, 
gradually decline with age. We succeeded in forming aggregates of Sg1 full length and 
Sg1 (1-159) fragment showing amyloid-like detergent stability, particle sizes as estimated 
by dynamic light scattering and fibrillar morphologies in TEM. Further we found that 
presence of Zn2+ substantially inhibit their amyloid aggregation in vitro.  Possibly, high 
Zn2+ found in seminal plasma of young individuals may have preventive role against 
aggregation of Sg1 in seminal vesicles.  
3.2 Introduction 
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In SSVA disorder, Sg1 amyloid deposits in the sub-epithelium and lumen of seminal 
vesicles and it would be expected to be of full length Sg1 as it would not have, thus far, 
encountered PSA. The fragmentation of Sg1 by PSA occurs after it is released out of the 
vesicles and mixed with prostatic fluid. Thus, amyloidogenicity of full length Sg1 needs 
to be examined to get a mechanistic insight into the development of SSVA. Also, 
examination of HIV infectivity in presence of full length Sg1 amyloid aggregates may be 
physiologically more relevant compared with the thus far obtained amyloid aggregates of 
Sg1 peptides which are generated only downstream post-ejaculation. In addition, 
amyloidogenicity of a large Sg1 (1-159) fragment encompassing the reported 
amyloidogenic peptide regions of Sg1 was also tested. 
Some metal ions such as Zn2+ and Cu2+ have been shown to inhibit amyloid formation of 
Aβ42 peptide which is implicated in development of Alzheimer’s disease [61,62]. Also 
Sg1 has been reported to have high affinity for Zn2+ [37]. As the semen of a young male 
contains high levels of Zn2+, which declines with age and the SSVA cases increase with 
age, we tested if Zn2+ has any effect on the aggregation of Sg1 in vitro that could influence 
the development of SSVA. 
We hypothesize that zinc plays a significant role in preventing the Sg1 protein to 
aggregate into amyloid like confirmation. As we know that seminal zinc concentration 
decreases with aging and the SSVA disorder occurs at an older age. At an older age zinc 
is no more available in concentrations that will check the protein from undergoing 
amyloid like aggregation. 
 
3.3 Results and Discussion 
3.3.1 Sg1 aggregation and amyloid formation 
3.3.1.1 Aggregation of Sg1 during dialysis  
The purified recombinant proteins Sg1 and Sg1 (1-159) were found to precipitate when 
dialysed at pH 7.4 and pH 9.0. Precipitation was observed even when dialysis was carried 
out in presence of 150 mM NaCl at alkaline pH. The precipitate was reasonably resistant 
to dilution as well as denaturation (up to 3.5 M urea), thus presence of amyloid-like 
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aggregates was suspected [10]. Therefore, the precipitates obtained at pH 9.0 were 
examined for amyloid-like aggregates. 
3.3.1.2 Assessment of amyloid aggregation of Sg1 and Sg1 (1-159) 
(i) Thioflavin-T binding assay 
We tested binding of amyloid specific dye ThT and examined its fluorescence emission 
spectrum when added to the precipitates of Sg1 full length (5 mg/ml) and Sg1 (1-159) 
fragment proteins [7]. The fluorescence emission intensity of ThT exhibited over four-
fold increase with concomitant shift in its emission maximum (λmax) to ~490 nm 
suggesting amyloid-like nature of the precipitates (Figure 25A and 25B).  
 
Figure 25. Assessment of amyloid nature of aggregates of Sg1 and Sg1 (1-159)  
Amyloid-like nature of aggregates was probed using Thioflavin-T (ThT) and 
Congo red binding assays [7,88]. ThT fluorescence emission spectra were recorded 
after mixing ThT (1.6 mM) with 5 mg/ml of full length Sg1 aggregates (A) or Sg1 
(1-159) fragment aggregates (B) that were obtained during dialysis of the protein 
purified in 8 M urea against the dialysis buffer (10 mM tris HCl, pH 9.0, 10 mM 
β-mercaptoethanol) at 4 °C. Congo red absorption spectra (300 nm-700 nm) were 
recorded after adding 1.4-fold excess of Congo red dye to Sg1 aggregates (C) or 
Sg1 (1-159) aggregates (D). Solid lines in spectra represent the aggregated protein 
 45 
 
 
whereas, the dotted lines indicate denatured protein in 8 M urea. Buffer controls 
are represented by the dashed lines. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26. Congo red birefringence of Sg1 and Sg1 (1-159) aggregates 
A & C are the bright field images of Sg1 full length and Sg1 (1-159) 
aggregates respectively and, B & D represent same fields viewed 
under cross-polarized light for Sg1 full length and Sg1 (1-159) 
aggregates respectively. 5 µl of Sg1 full length or Sg1 (1-159) 
aggregates (12 mg/ml) were mixed with 400 µM Congo red dye and 
allowed to bind for 1 hour similar to the protocol described by 
O'Nuallain et al, 2004. Birefringence was observed using Leica 
microscope DM2500 under cross-polarized light at 40X 
magnification. 
(ii) Congo red binding assay 
a) Congo red absorbance spectrum: To further confirm the amyloid-like nature, 
when Congo red was incubated with the precipitates, its absorption maximum 
showed red shift (480 nm to 530 nm) consistent with Congo red binding to 
amyloid-like aggregates (Figure 25C and 25D). While Congo red binding to 
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amyloids can also lead to increase in its absorption intensity [88], similar to the 
observation here for Sg1, the Congo red binding to some amyloids like that of β2-
microglobulin leads only to red shift in the λmax towards 540 nm but not 
accompanied by significant absorption intensity increase [89].   
b) Congo red birefringence: Polarized light microscopy of Congo red-stained 
aggregates was carried out by using the protocol as described previously [90]. Sg1 
and Sg1 (1-159) aggregates exhibited Congo red birefringence when incubated 
with Congo red and viewed under polarized light (Figure 26). 
 
3.3.2 Stability assessment of Sg1 aggregates  
3.3.2.1 Semi denaturing detergent agarose gel electrophoresis (SDD-AGE) 
For amorphous protein aggregates, addition of detergents such as SDS or sarkosyl, even 
at room temperature, can penetrate and break apart the aggregates into monomers. On the 
contrary, as amyloid aggregates are formed of several levels of structural organization 
from monomers to β-sheet-rich oligomers and then into protofibrils and finally into 
fibrils, addition of detergents at room temperature fail to completely dissociate the 
monomers unless heated at very high temperatures such as close to boiling [91]. Amyloid 
aggregates are found to have high stabilities against physical and chemical denaturants 
and proteolysis [23]. Several amyloid and prion proteins also exhibit modest stability at 
room temperature to detergents (up to 1-2%) like SDS (e.g. Aβ42 amyloid) or Sarkosyl 
(e.g. HET-s prion amyloid) [92]. Thus, the Sg1 protein precipitated during dialysis was 
examined for stability against SDS and sarkosyl by SDD-AGE method [91]. Where after 
pre-incubation with the detergent (1 or 2%) at room temperature, the samples were 
electrophoresed on 1.5 % agarose gel and visualized by electro-blotting to PVDF 
membrane and Coommassie staining. 
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Figure 27. Detergent stability of Sg1 and Sg1 (1-159) amyloid aggregates 
Sg1 aggregates (40 µg) obtained upon dialysis were incubated with 1 % SDS at 
room temperature (RT) for 10 min and size of aggregates was analyzed using 
SDD-AGE [91] by electrophoresis on 1.5 % agarose gel followed by 
electroblotting to PVDF membrane and protein detection by Coommassie 
staining (A). The aggregates of Sg1 and Sg1 (1-159) were also incubated in 
presence of 2 % sarkosyl at RT and analyzed similarly by SDD-AGE (B). To 
obtain monomeric controls, the aggregates (12 µg) were incubated with 8 M urea 
and then heated at 99°C for 10 min in presence of 1 % SDS (A) or 2 % sarkosyl 
(B) before electrophoresis. In panel (B) the HEWL monomer was used to mark 
14 kDa position. (C) A combinatorial effect of 1 % sarkosyl and heat on the size 
of aggregates was also examined by SDD-AGE after incubation at RT, 37°C or 
65°C for 10 min. 
 
 
When treated with 1 % SDS most of the precipitated protein was found to convert to 
monomers, suggesting a partial resistance of Sg1 full length aggregates to 1 % SDS 
(Figure 27A). As the resistance to SDS mediated disaggregation was minimal, we tested 
stability of aggregates against 2 % sarkosyl and found that both Sg1 full length and Sg1 
(1-159) aggregates exhibited high molecular weight species suggesting stability against 
2 % sarkosyl (Figure 27B). The observed high molecular weight smear on SDD-AGE in 
presence of detergents is expected if the aggregates had amyloid-like property. As 
 48 
 
 
expected, when the aggregates pre-incubated in presence of 1 % sarkosyl were heated to 
65°C higher molecular weight aggregates were seen to break down to smaller aggregates 
although they resisted disaggregation up to 37°C when tested (Figure 27C). Previous 
studies on stabilities of [PIN+] aggregates have shown disaggregation when heated to 
60°C with SDS [93]. 
3.3.2.2 Proteinase-K resistance 
Several amyloid and prion proteins have also been reported to exhibit resistance to 
proteinase-K digestion albeit to different extents, possibly due to their compact structure 
causing inaccessibility of the core [6]. When we examined the proteinase-K resistance of 
Sg1 aggregates and analyzed by tricine SDS-PAGE the aggregates exhibited full 
resistance to proteinase-K digestion even after 15 min as seen by the residual protein 
intensity of the monomer (Figure 28). The non-aggregated protein, when treated similarly 
was found amenable to proteinase-K digestion and the residual protein monomer was 
found to significantly decrease (Figure 28). The observed stability of the Sg1 aggregates 
to proteinase-K digestion is consistent with as expected of amyloid-like aggregates. 
 
Figure 28. Partial resistance of Sg1 amyloid aggregates to Proteinase-K digestion 
Sg1 aggregates or monomers (0.7 µg/µl) were incubated at 37°C with 
Proteinase-K (PK) at PK/aggregate ratio of 1:2000. The aliquots were 
removed at 0, 5 and 15 min and proteolysis was stopped by addition of 5 
mM PMSF. Samples were electrophoresed on Tricine SDS-PAGE (16%) gel 
and protein was visualized using Coommassie [94]. The monomeric protein 
used for comparison was pre-obtained by dialysis of the purified protein at 
pH 3.0 with 2 M urea. The presence of urea (2 M) did not inhibit PK activity 
as reported previously [10]. 
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3.3.3 Kinetics of in vitro amyloid aggregation of Sg1 
3.3.3.1 Effect of pH on aggregation trend of Sg1 
For many amyloid proteins the in vitro aggregation into amyloid conformation follows a 
signature lag-dependent sigmoidal kinetics [5]. When re-solubilized Sg1 full length 
protein was incubated at different pH with intermittent agitation and monitored for 
aggregation by ThT binding, the aggregation was observed at basic pH but not under 
acidic pH conditions (Figure 29). A lag dependent sigmoidal kinetics of aggregation for 
Sg1 protein was observed at pH 9.4 suggesting it to be the optimal pH (Figure 29). This 
bears a parallel to the in vivo alkaline pH of the seminal vesicles where Sg1 aggregates 
and deposits [57]. 
 
 
Figure 29. Sg1 aggregation at different pH 
Full length Sg1 (12 mg/ml) was incubated with ThT at 30°C at different pH 
(2.0 to 10.5) along with 1 M urea and agitated intermittently. ThT 
fluorescence emission intensity at 485 nm was recorded every 5 min using 
Spectramax- M5e microplate reader. 
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3.3.3.2 Comparative aggregation kinetics 
When Sg1 and Sg1 (1-159) proteins were examined for aggregation under similar 
conditions, the kinetic trends obtained for the two proteins were amyloid-like, however, 
non-overlapping (Figure 30A). The aggregation of Sg1 (1-159) seemed to reach 
saturation by ~ 60 hrs of incubation whereas, Sg1 aggregation required ~80 hrs to peak.  
 
 
Figure 30. Aggregation of Sg1 (1-159) compared with Sg1  
(A) 12 mg/ml of Sg1 (solid line ) or Sg1 (1-159) fragment (dotted line) were 
incubated in presence of 0.5 M GuHCl and 1.5M urea,100 mM β-mercaptoethanol 
with ThT at 30°C, pH 9.0 and agitated (200 rpm) in shaking incubator. ThT 
fluorescence emission was recorded at 485 nm after withdrawing aliquots at intervals 
of 20 hrs. Using triplicate samples, error bars representing standard deviation were 
obtained. A blank containing all the constituents except the protein was used for 
comparison (dashed line). (B) The aggregates of Sg1 and Sg1 (1-159) were incubated 
in presence of 1 % sarkosyl at RT and analyzed by SDD-AGE. Lane 1 and 3 
represent sarkosyl stability of Sg1 (1-159) and Sg1full length aggregates formed 
after 86 hrs of incubation in aggregation buffer; lane 2 and 4 have monomeric Sg1 
(1-159) and Sg1 respectively; lane 5 represents higher molecular weight aggregates 
of Sg1 (1-159) obtained upon dialysis in aggregation buffer containing 0.25 M 
GuHCl and 1 M urea, pH 9.0 at 30°C with shaking. 
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The observed rapid aggregation of Sg1 (1-159) is analogous to reports of faster 
aggregation of some other amyloid and prion domains compared to their full-length 
proteins [95]. Prolonged incubation after the ThT fluorescence had reached saturation 
lead to decline in ThT fluorescence intensity, similar to previously reported trend for other 
amyloids like that of the Rnq1 prion protein [10]. Further suggestive of amyloid-like 
aggregation, detergent stability was also observed for the samples which displayed 
amyloid-like sigmoidal kinetics monitored by ThT fluorescence increase (Figure 30B, 
Lane 1 and 3).   
 
3.3.4 Secondary structure estimation by Circular dichroism 
Circular dichroism (CD) spectroscopy technique makes use of the fact that chiral 
molecules will interact differently with right and left circularly polarized light. Peptides 
and proteins have chiral properties with the amide group in the peptide bond being main 
chromophore in far-UV region (190-260 nm) of CD spectrum [85]. 
 
 
  Figure 31. Far-UV Circular dichroism spectra of Sg1 and Sg1 (1-159) aggregates 
CD spectra of Sg1 (A) and Sg1 (1-159) (B) aggregates formed upon dialysis 
against aggregation buffer (pH 9.0) were recorded after diluting the aggregates 
(final: 2 mg/ml) in the same buffer, using Jasco J-1500 spectropolarimeter and 
1mm path length quartz cuvette. Data is represented as mean residue ellipticity 
(MRE). CD spectra of denatured Sg1 (A) and Sg1 (1-159) (B) in 6 M GuHCl 
(dashed line) was recorded for comparison. 
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CD spectra have earlier reported native Sg1 to be largely unstructured while a small 
peptide that converted into hydrogel with amyloid-like characteristics, has displayed β-
sheet rich conformation [52,76]. Change in secondary structure of Sg1 and Sg1 (1-159) 
upon aggregate formation was analyzed by Far-UV CD spectroscopy in the wavelength 
range 190-260 nm. Increase in β sheet content was hinted by the negative ellipticity 
around 215 nm (Figure 31A and 31B). The denatured proteins in 6 M GuHCl showed 
largely unstructured conformation.  
 
3.3.5 Transmission electron microscopy of Sg1 and Sg1 (1-159) aggregates 
Transmission electron micrographs of Sg1 and Sg1 (1-159) aggregates were obtained 
after diluting the aggregates in aggregation buffer, pH 9.0. For improving contrast 
samples were negatively stained with 0.2 % phosphotungstic acid. TEM of Sg1 peptides 
have previously been reported to exhibit fibrillar structures >500 nm in size [48]. Here 
Sg1 and Sg1 (1-159) aggregates showed fibrillar structures of varying sizes and 
morphologies suggesting their amyloid nature. In the TEM images straight, twisted, short 
and very well grown fibres were also observed (Figure 32). 
 
3.3.6 Estimation of Sg1 aggregate sizes by Dynamic light scattering (DLS) 
After confirming that the formed aggregates are amyloid-like ordered aggregates and not 
amorphous aggregates. Dynamic light scattering was performed to examine the particle 
size of the aggregates. DLS measures time-dependent fluctuations in the scattering 
intensity arising from particles undergoing random Brownian motion. Analysis of these 
fluctuations can be used to obtain information about Diffusion coefficient and particle 
size. Decay in correlation function is related to the motion of the particle specifically to 
the diffusion coefficient. The method provides ability to measure size characteristics of 
proteins in a liquid medium [96]. Previously reported DLS data for fragments of Sg1 
showed amyloid aggregates of varying sizes some of them were nearly 500 nm in size 
[52,53]. Full length Sg1 and Sg1 (1-159) aggregates obtained upon dialysis at pH 9.0 
were diluted into aggregation buffer such that final concentration is 2 mg/ml. 
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   Figure 32. Transmission electron micrographs of Sg1 and Sg1 (1-159) aggregates  
Sg1 aggregates (A-D) and Sg1 (1-159) aggregates (E-H) formed after 
dialysis in 10 mM Tris-HCl, pH 9.0 buffer in presence of 10 mM β-
mercaptoethanol were analysed by high resolution TEM (T20G2), 
operated at 200 kV . Scale bars are indicated on each image. Arrows 
indicate towards fibrillary aggregates. 
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Dynamic light scattering measurements were carried out at room temperature using Delsa 
Nano C Particle Analyzer (Beckman Coulter) and data were processed using Delsa Nano 
3.7 software. Measurements were carried out using 1 ml quartz cuvette with the sample 
chamber pre-maintained at 25 °C.  
 
 
Figure 33. Estimation of Sg1 and Sg1 (1-159) aggregate sizes by DLS 
Scattering measurements were carried out on (A) Sg1 and (B) Sg1 (1-159) aggregates 
formed at pH 9.0. Samples were diluted in aggregation buffer to final concentration of 
2 mg/ml at room temperature before recording the spectrum. 
DLS measurements of Sg1 aggregates showed large size aggregates of ~ 500-700 nm 
thereby indicating the formation of higher size entity which is consistent with amyloid-
like aggregation (Figure 33). From the number distribution of the molecular species from 
DLS data, the mean hydrodynamic radii obtained for the samples were: Sg1 aggregates: 
576 ±	167 nm (polydispersity: 30.6 %); Sg1 (1-159) aggregates: 799 ± 212 nm 
(polydispersity: 71 %). 
 
3.3.7 Inhibition of Sg1 aggregation by Zn2+ 
Significant reduction in seminal levels of Zn2+ has been observed with male aging and it 
correlates with increased infertility [54]. The Sg1 protein has previously been reported to 
have remarkable affinity for Zn2+ [37] . We examined whether a correlation exists between 
decline in Zn2+ levels and increased aggregation of Sg1 leading to SSVA which is a late-
onset disorder affecting male reproductive system. When the effect of Zn2+ was 
investigated on the amyloid aggregation of Sg1 and Sg1 (1-159) proteins Zn2+ was found 
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to inhibit the aggregation when present at 15-fold molar excess (Figure 34A). For both 
the proteins equimolar Zn2+ was found to be nearly non-inhibitory whereas, the 15 fold 
excess Zn2+ was highly inhibitory causing ~ 70-90 % reductions in their aggregation as 
monitored by ThT fluorescence. Unlike the inhibition by Zn2+, there was no reduction in 
Sg1 aggregation in presence of an organic compound 3AP (Figure 34B) belonging to the 
class of aminophenols which were previously found to prevent aggregation of Aβ42 and 
HEWL in vitro [97,98]. Although, Zn2+ has been previously found to inhibit Alzheimer’s 
disease Aβ42 peptide’s aggregation [62], the finding here that it indeed also inhibits Sg1 
aggregation could influence the understanding of SSVA in the view of the importance of 
Zn2+ to the male reproductive system. Although, many promiscuous inhibitors have been 
shown for amyloids, the observed inhibition here by Zn2+ of Sg1 amyloid aggregation in 
vitro, may be specific due to the relevance of Zn2+ to male reproductive system and the 
previously reported presence of Zn2+ binding sites on the Sg1 protein [54, 55].  
 
 
 Figure 34. Aggregation of Sg1 and Sg1 (1-159) fragment in presence of Zn2+or 3- aminophenol 
   (A) Aggregation of Sg1 full length and Sg1 (1-159) fragment (12 mg/ml) were examined 
in presence of equimolar Zn2+ or in 15-fold molar excess of Zn2+ by ThT fluorescence assay. 
After 88 hrs of incubation ThT fluorescence of the samples was compared with a positive 
control lacking Zn2+, the ThT fluorescence of which was considered as 100%. Error bars 
represent standard deviation. (B) Effect of 3-aminophenol on Sg1 amyloid aggregation was 
assessed by incubating the protein samples (12 mg/ml) Sg1 full length or Sg1 (1-159) 
fragment with 4 molar excess of 3AP under similar aggregation conditions and recording 
ThT fluorescence intensity after 88 hrs of incubation as above. Data presented here after 
appropriate baseline corrections, where Zn2+ or 3AP were found to have no interference to 
ThT fluorescence assay.  
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The findings here of amyloid-like aggregation of Sg1 and Sg1 (1-159) proteins and the 
inhibition of the aggregation by Zn2+ may have implications towards therapeutic strategies 
for SSVA which may be imminent especially as Sg1 amyloid is reported to enhance HIV 
infectivity in cell cultures. 
 
3.4 Materials and Methods 
3.4.1 Materials 
Thioflavin-T, N-Lauroylsarcosine sodium salt (Sarkosyl), Sodium dodecyl sulfate (SDS), 
β-mercaptoethanol, Proteinase-K, Polyvinylidine fluoride (PVDF) membrane were from 
GE Healthcare. 96 microwell plate from Thermo scientific (US). Sodium phosphate 
monobasic, Sodium phosphate dibasic, Zinc chloride were of molecular biology grade 
and procured from HiMedia (India). 3-Amino phenol (catalog no. A11943) was obtained 
from Alfa Aesar (India). All other chemicals were of high purity. 
3.4.2 Sg1 aggregation and amyloid formation 
3.4.2.1 Assessment of amyloid aggregation of Sg1 and Sg1 (1-159) 
(i) Thioflavin-T binding assay 
Thioflavin-T is a planar organic dye reported to bind specifically to amyloid aggregates 
upon which its fluorescence properties significantly change [7]. Extrinsic fluorescence 
spectrum of ThT upon amyloid binding was measured by exciting at 442 nm and 
recording emission from 460 nm to 560 nm. An enhanced ThT fluorescence emission 
intensity at 485 nm- 490 nm usually indicates binding to amyloid-like conformation [7]. 
ThT fluorescence was either monitored upon incubating samples with intermittent 
shaking in Spectramax- M5e microplate reader (Molecular Devices) or aliquots were 
examined at intervals (20 hrs) from samples incubated in constant shaking incubator. 
Agitation has been shown previously to accelerate amyloid aggregation for several 
amyloids which is attributed to be due to role of air-water interface or faster fragmentation 
of large size agglomerates of amyloid aggregates [10,13,83,99]. 
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(ii) Congo red binding assay 
a) Congo red absorbance spectrum: Congo red dye is known to bind to amyloid 
aggregates, which results in a red shift in its absorbance maximum (λmax) from 
480 nm to 540 nm [88]. To assess the amyloid nature of Sg1 and Sg1 (1-159) 
aggregates, a 400 µM Congo red stock solution was prepared in PBS buffer, pH 
7.4 ( 0.137 M NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, 8.1 mM Na2HPO4) with 0.4 
% ethanol to avoid micelle formation [88].  Congo red (122 µM) was mixed with 
87 µM of the sonicated protein precipitate of full length Sg1 and Sg1 (1-159). The 
samples were allowed to incubate for 15 minutes at room temperature. Congo red 
binding assay was performed by recording absorbance from 300 nm-700 nm to 
examine the shift in λmax. [88].  The sample showed red shift from 480 nm to 530 
nm, supporting the amyloid nature of the precipitate obtained during dialysis of 
full length Sg1 as well as for Sg1 (1-159) fragment. 
b) Congo red birefringence: 5µl of Sg1 full length or Sg1 (1-159) aggregates (12 
mg/ml) were mixed with 400 µM Congo red dye and allowed to bind for 1 hour 
similar to the protocol described by O'Nuallain et al, 2004 [90]. Birefringence was 
observed using Leica microscope DM2500 under cross-polarized light at 40X 
magnification. 
 
3.4.3 Kinetics of in vitro amyloid aggregation of Sg1 
3.4.3.1 Effect of pH on aggregation trend of Sg1  
To screen the conditions required for amyloid like aggregate formation and determine the 
buffer conditions optimum for Sg1 aggregation, aggregation kinetics of Sg1 was assessed 
at different pH (pH 2.0 - 10.5). For the aggregation assay, the protein precipitate of Sg1 
obtained during dialysis at pH 7.4 (10 mM sodium phosphate buffer, 10 mM β-
mercaptoethanol) was first re-solubilized in 5 M urea and then diluted in different pH 
buffers ranging from pH 2.0 to 10.5 to obtain 12 mg/ml protein and 1M urea 
concentrations. Samples were incubated at a constant temperature of 30 °C, along with 
agitation for 30 seconds every 5 minutes using auto-mix function which permits linear 
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shaking in Spectramax- M5e microplate reader to promote aggregate formation.  Samples 
were monitored for amyloid formation by ThT fluorescence measurement. 
3.4.3.2 Comparative aggregation kinetics 
In order to examine the comparative aggregation kinetics of Sg1 and Sg1 (1-159), the 
protein precipitates obtained from dialysis at pH 9.0, were first re-solubilized in 6 M 
GuHCl and then diluted to final 0.5 M GuHCl in aggregation buffer (0.25 M Tris HCl pH 
9.0 with 1.5 M urea and 100 mM β-mercaptoethanol ). Samples were added with ThT 
(1.6 mM) and agitated (200 rpm) in orbital shaking incubator at 30°C and monitored for 
amyloid aggregation at intervals of 20 hrs.  
 
3.4.4 Stability assay of Sg1 aggregates  
3.4.4.1 Semi denaturing detergent agarose gel electrophoresis (SDD-AGE)  
Unlike amorphous protein aggregates, many amyloid and prion aggregates exhibit modest 
stability to detergents like SDS or sarkosyl (~1-2 %) at room temperature [23,92]. 
Stability against detergents is one of the key features of amyloid where the bulky 
aggregates only partially disassemble on treatment with ionic detergents. For assessing 
the detergent stability of Sg1 and Sg1 (1-159) amyloid aggregates at room temperature a 
method called Semi Denaturing Detergent Agarose Gel Electrophoresis (SDD-AGE) was 
used. This method was described by Bagriantsev, S.N. et al. in the year 2006 [91].  Since 
the aggregates are bigger in size they cannot be analysed in polyacrylamide gel which has 
small pores. The pore size is not sufficient for the passage and resolution of amyloid like 
aggregates thus agarose gel was used for running large protein polymers. This method 
enables the characterization of large protein polymers which are stable in SDS or Sarkosyl 
at room temperature. The Sg1 and Sg1 (1-159) aggregates were incubated with 1 % SDS 
or 2 % sarkosyl at room temperature for 10 min with non-reducing Laemmli sample 
buffer and examined on 1.5 % agarose gel by electrophoresis followed by electroblotting 
to PVDF membrane using SDD-AGE method as described previously [78,91]. The 
proteins on the PVDF membrane were visualized by staining with Coommassie brilliant 
blue R-250 [78,91]. 
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Amyloid aggregates can be resolved based on their size and detergent insolubility using 
the method SDD-AGE. The process involves the following five steps:  
 1. Preparation of agarose gel  
 2. Preparation of protein samples  
 3. Agarose gel electrophoresis  
 4. Transfer to Polyvinylidene difluoride (PVDF) membrane  
 5. Detection of protein on PVDF membrane  
 
Buffers and reagents:  
Buffer for making agarose gel (1.5%): Tris 20 mM, Glycine 200 mM, Agarose 1.5 %, 
SDS 0.1%; Sample buffer (4x) without SDS and DTT: Tris 240mM, Bromophenol blue 
0.2%, Glycerol 20%; Electrophoresis running buffer: Tris 20 mM, Glycine 200 mM, SDS 
0.1%; Transfer buffer: Tris 20 mM, Glycine 200 mM, SDS 0.1 %, Methanol 15%; 
Staining solution: 0.4 g Coommassie brilliant blue R-250, methanol 30%, acetic acid 10% 
and water 60%; Destaining solution: Methanol 40%, acetic acid 10%, water 50%. 
 
 
Step 1: Preparation of agarose gel  
a) 1.5% agarose gel was prepared in tris-glycine buffer. The weighed amount of  
  agarose was completely dissolved using microwave.  
b) After agarose melted 0.1% SDS was added drop wise from 10% stock with   
   gentle swirling to avoid bubble formation.  
c) Agarose solution was then poured into the casting tray enough for submerging 
the comb teeth.  
d) After the gel was set, comb was removed and the gel was placed in the gel tank  
  containing the electrophoresis buffer with 0.1% SDS.  
Step 2: Preparation of protein samples  
a) To an aliquot of protein sample, SDS or sarkosyl solution was added from 10%  
   stock such that the final concentration of the ionic detergent becomes 2 %.  
b) The mixture was incubated for 10 min at room temperature to check for the          
stability of amyloid aggregates against the used ionic detergent. 
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Step 3: Agarose gel electrophoresis  
a) From the 4X stock of sample buffer, aliquots were added to the samples to get a 
mixture containing 1X sample buffer.  
b) Samples containing 1X sample buffer were incubated at room temperature for 
10 minutes and were then loaded on gel.  
 c) The gel was allowed to run at 125 volts for half an hour.  
Step 4: Transfer to PVDF membrane  
a) A piece of PVDF membrane was cut to the same dimensions as the agarose gel.  
b) To activate the PVDF membrane it was submerged in methanol for 1 minute and    
then rinsed with distilled water followed by soaking it in transfer buffer. 
          c) Two pieces of blotting paper were also cut in same dimensions as gel.  
        d) In a tray, both the blotting paper and the activated PVDF membrane were then 
   soaked in transfer buffer.  
     e) The agarose gel was trimmed and oriented by making a cut in the lower right 
 corner.  
f) Then each module was assembled in the following order starting from the bottom 
 electrode plate (the cathode): First a black foam mesh was placed at the bottom of 
electrode plate, then a thick absorbent/blotting paper, thoroughly soaked in 
transfer buffer, the agarose gel, the wet PVDF membrane, a thick absorbent paper, 
a single foam mesh and then the upper electrode (the anode).  
 g) While assembling the stack, care must be taken to avoid any bubble entrapping 
 between the gel and the membrane which may hinder the transfer of protein. 
    h) The electrodes were then connected and transfer was allowed to proceed for a 
 minimum of 2.0 hours at 100 volts, at 4°C.  
Step 5: Detection of protein on PVDF membrane  
 After transfer, the membrane was stained with Coommassie R-250 for 10 minutes. 
 Followed by destaining using destaining solution and the image was captured 
 using gel doc (G-box, syngene).  
 
3.4.4.2 Proteinase-K resistance  
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Several amyloid aggregates have been reported to exhibit moderate resistance to digestion 
by proteinase-K [10,23]. The aggregated Sg1 full length protein (14 µM) was incubated 
with proteinase-K (0.3 µg/ml) at 37 °C for 0, 5 or 15 min in protease assay buffer (10 mM 
Tris HCl, 5 mM CaCl2, pH 7.8). The proteolysis reaction was terminated by adding 5 mM 
PMSF and samples were mixed with reducing SDS-sample buffer and boiled for 6 min at 
96°C before electrophoresis on 16% Tricine SDS-PAGE [94], which can give better 
resolution of small peptides and protein fragments [94]. Protein was visualized by prior 
fixing of the gel in fixing solution (50 % methanol, 10 % acetic acid, 100 mM ammonium 
acetate) for 30 mins followed by staining with Coommassie brilliant blue R-250.  
 
 
3.4.5 Secondary structure estimation by CD 
Sg1 and Sg1 (1-159) aggregates formed upon dialysis at pH 9.0 in presence of 10 mM 
β-mercaptoethanol  were examined for any change in secondary structure using Far-UV 
circular dichroism (CD) spectroscopy. Sg1 and Sg1 (1-159) aggregates were diluted (~ 
thirty fold) in 10 mM tris HCl, pH 9.0 buffer, before acquiring the CD spectra [100]. 
CD spectra were recorded using Jasco J-1500 spectropolarimeter in the wavelength 
range of 190-260 nm using cuvette of 1mm path length and 2 mg/ml protein. Mean 
residue ellipticity [θ] was calculated using the following equation: 
[θ]= (θobs * MRW) / (10*c*l) 
Where, θobs, c, l and MRW represent the observed ellipticity in milli-degrees, protein 
concentration in mg/mL, path length of cuvette in cm, and mean residue weight taken as 
112 Da respectively. The spectra were corrected for baselines.  
3.4.6 Transmission electron microscopy (TEM) of Sg1 and Sg1 (1-159) aggregates 
The transmission electron micrographs of Sg1 and Sg1 (1-159) aggregates were acquired 
using a high-resolution transmission electron microscope (FEI Tecnai, T20G2), operated 
at 200 kV. A drop of the suspension was placed on a carbon-coated copper grid, dried in 
desiccator and negatively stained with 0.2 % Phosphotungstic acid (PTA) for 2 minutes, 
before imaging. 
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3.4.7 Estimation of Sg1 aggregate sizes by DLS 
Full length Sg1 and Sg1 (1-159) aggregates obtained upon dialysis at pH 9.0 were diluted 
into aggregation buffer such that final concentration is 2 mg/ml. Dynamic light scattering 
measurements were carried out at room temperature using Delsa Nano C Particle 
Analyzer (Beckman Coulter) and data were processed using Delsa Nano 3.7 software. 
Measurements were carried out using 1 ml quartz cuvette with the sample chamber pre-
maintained at 25 °C. The samples were illuminated with a 658 nm laser light and 
scattering intensity were measured at 165° angle. 
3.4.8 Inhibition of Sg1 aggregation by Zn2+ 
Reduction in seminal levels of zinc has also been reported with aging [54]. Therefore, it 
was investigated whether Zn2+ can exert any effect on the in vitro aggregation of Sg1. 
Any in vitro effect of Zn2+ if further corroborated by in vivo investigations, could show 
role of Zn2+ concentration on Sg1 aggregation and the development of SSVA. For this, a 
stock solution of ZnCl2 (30 mM) was prepared in 10 mM tris HCl pH 9.0 buffer and used 
for the studies. 12 mg/ml  Sg1 and Sg1 (1-159) fragment were incubated with Zn2+ 
solution to obtain molar ratios of 1:1 or 1:15 and aggregation was examined by ThT 
binding assay in presence of 100 mM β-mercaptoethanol. Certain aminophenols such as 
p-aminophenol, have been reported to disaggregate amyloid aggregates of Aβ42 peptide 
and hen egg white lysozyme protein (HEWL) when incubated at equimolar ratios [97,98]. 
Here, we tested whether 3-aminophenol (3AP) at four-fold molar excess would have any 
effect on the aggregation of Sg1 or Sg1 (1-159) fragment. 
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Chapter IV 
 
 
New insights into amyloid-like 
in vitro aggregation of human serum albumin protein 
  
 
4.1 Abstract 
Amyloid aggregates display striking features of detergent stability and self-seeding. 
Human Serum Albumin (HSA), a preferred drug-carrier molecule, can also aggregate in 
vitro. So far, key amyloid properties of stability against ionic detergents and self-seeding, 
are unclear for HSA aggregates. Precautions against amyloid contamination would be 
required if HSA aggregates were self-seeding. Here, we show that HSA aggregates 
display detergent sarkosyl stability and have self-seeding potential. HSA dimer is 
preferable for clinical applications such as a plasma expander, due to its longer retention 
in circulation and lesser oedema owing to its larger molecular size. Here, HSA was homo-
dimerized via free cysteine-34, without the use of any potentially immunogenic cross-
linkers that are usually pre-requisite for HSA homo-dimerization. Alike the monomer, 
HSA dimers also aggregated as amyloid, necessitating considerations for precautions 
while using for therapeutics. 
 
 
4.2 Introduction 
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Human serum albumin (HSA) which is the most abundant protein in blood plasma, can 
form amyloid-like aggregates in vitro [71,72]. HSA is an all-α helix, globular protein 
made of  a single peptide chain of 585 amino acids with one free sulfhydryl group at 
cysteine-34 [63]. It has multiple physiological roles like: as a nutrients transporter & 
carrier protein in blood for several compounds (e.g.: fatty acids, amino acids, bile salts, 
metals and hormones etc.) and as a regulator for blood pH & osmotic pressure [65-67]. It 
has also found applications as a safe and non-immunogenic drug carrier and as a versatile 
plasma expander, as its administration is considered to be helpful in the treatment of 
severe hypoalbuminemia during burns, nephritic syndrome, chronic liver cirrhosis and 
haemorrhagic shocks [68]. Notably, HSA dimers are preferable as a plasma expander as 
well as a drug carrier due to their increased circulatory life and alleviating effect on the 
oedema associated with unwanted extravasation of the monomeric HSA [68,69].  
HSA has been used as a model amyloid protein and is found to form amyloid-like 
aggregates in vitro at physiological pH 7.4 and also at acidic pH but only at elevated 
temperatures, when present in aqueous solvents [71]. HSA aggregation has been reported 
at physiological pH at lower temperatures also (25°C, 37°C, 65°C) however in presence 
of organic solvent ethanol [72-74]. HSA aggregates display varying morphologies under 
different aggregation conditions, possibly due to formation of different structural 
intermediates during the  aggregation pathway  [71,72]. Unlike a typical amyloid 
aggregation trend, which follows a lag dependent sigmoidal kinetics, there is absence of 
any apparent lag period in HSA aggregation [5,72]. Although HSA aggregates conform 
to several amyloid aggregate-associated properties such as thioflavin-T (ThT) dye 
binding and Congo red binding, certain important properties such as the self-seeding 
ability and detergent stability have not been established yet. Amyloid self-seeding is 
usually assayed in vitro and monitored as decrease in lag period of aggregation, 
suggesting acceleration of conversion of monomers to aggregates [10]. If HSA aggregates 
exhibited self-seeding at physiological conditions, any unwanted HSA amyloid 
contamination in samples used for therapeutics, could potentially seed the in vivo 
circulating HSA monomers into amyloid form, which would be hazardous.   
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Here we first converted HSA into aggregates exhibiting amyloid-like ThT dye binding 
and then we examined if the aggregates display amyloid-like detergent stability. 
Furthermore, we examined self-seeding behaviour of HSA aggregates at sub-optimal 
aggregation temperature, in the view that few previous attempts at optimal aggregation 
conditions were inconclusive, possibly due to lack of a discernible lag period in 
aggregation [72,75]. Due to buried nature of the free cysteine-34 in HSA structure, HSA 
dimers employed for clinical applications have often been obtained using chemical cross-
linkers of cysteine, which may potentially be immunogenic [68]. Here we succeeded in 
homodimerizing HSA via disulfide linkage using denaturation in urea and hydrogen 
peroxide (H2O2) induced oxidation. We then examined if HSA homodimers retain the 
amyloidogenic properties similar to the HSA monomers.  
 
4.3 Results and Discussion 
4.3.1 In vitro formation of HSA aggregates  
Temperature is important factor in HSA protein aggregate formation. Elevated 
temperature favoured aggregation as it might promote partial unfolding. HSA protein was 
diluted in aggregation buffer (10 mM sodium phosphate buffer pH 7.4 containing 50 mM 
NaCl) to a final concentration of 20 mg/ml and incubated without agitation at 65°C for 
52 hrs in a water bath to induce aggregation as reported previously [71,72]. Amyloid 
aggregate formation was assessed by ThT and Congo red binding assays as described 
below.  
(i) Thioflavin-T binding assay for HSA aggregates 
ThT dye has been reported to bind specifically to amyloid aggregates which 
changes its fluorescence properties significantly [7]. HSA aggregates (20 mg/ml) 
were mixed with ThT solution (2 mM final) and extrinsic fluorescence emission 
spectrum of ThT was monitored by excitation at 442 nm and recording emission 
from 460 nm to 560 nm. HSA aggregates showed an enhanced ThT fluorescence 
emission intensity around 485 nm indicating amyloid-like ThT binding (Figure 
35A) as also reported previously [72]. Excitation spectra of ThT, after addition to 
HSA aggregates, was also recorded between 250-455 nm after fixing the emission 
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to 495 nm [7]. HSA aggregates showed ThT fluorescence excitation maxima near 
450 nm (Figure 35B).  
 
Figure 35. Assessment of amyloid nature of HSA aggregates by ThT fluorescence 
HSA aggregates formed by incubation at 65°C for 52 hrs were added with ThT 
and fluorescence emission spectrum (A) and ThT excitation spectrum (B) of these 
aggregates were recorded. Solid lines in both panels A and B represent ThT 
spectra with HSA aggregates and dashed lines indicate buffer control spectra. 
 
(ii) Congo red binding assay for HSA aggregates 
The dye Congo red can bind to amyloid aggregates with high specificity, which can 
manifest as a red shift in its absorption maximum (λmax) from 480 nm to 540 nm or 
increase in absorption intensity in 480-540 nm range [88].  
 
Figure 36. Congo red absorbance spectrum in presence of HSA aggregates 
Congo red absorption spectrum of HSA aggregates (solid line) 
formed upon incubation of HSA at 65°C for 52 hrs. Dashed line 
represent Congo red spectrum of free dye in buffer, pH 7.4. 
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Congo red absorption spectrum was recorded from 300 nm to 400 nm after mixing 
it with HSA aggregates in 1:1 molar ratio. Congo red absorption maximum of free 
dye at 480 nm shifted to 540 upon binding to HSA aggregates indicative of amyloid-
like aggregation (Figure 36). 
4.3.2 Intrinsic tryptophan fluorescence of HSA aggregates 
  Intrinsic fluorescence of Tryptophan residues is a good parameter to study folding and 
unfolding of a protein [101]. When amyloid formation occurs, Trp residues present on the 
surface (hence in hydrophilic micro-environment) of the native protein may be expected 
to get internalized (hence in hydrophobic micro-environment) leading to change in the 
Trp fluorescence emission pattern. Thus, Trp fluorescence emission spectra was recorded 
(excitation wavelength at 292 nm; emission scan 300-400 nm) to study HSA amyloid 
formation as it contains surface Trp residues in its native conformation [102]. In native 
state monomeric HSA protein gives Trp fluorescence emission λmax at 340 nm which 
undergoes blue shift to 332 nm upon HSA aggregation (Figure 37). 
 
Figure 37. Tryptophan fluorescence emission spectra of HSA aggregates 
Tryptophan fluorescence emission spectra was recorded 
(excitation at 292 nm; emission scan 300-400 nm) to examine HSA 
amyloid formation. HSA aggregates (solid line) showed a blue 
shift in Trp emission maximum from 340 nm to 332 nm as 
compared to monomeric HSA protein (solid dots). Spectra shown 
with dashed line represent buffer control. 
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4.3.3 Estimation of molecular sizes of HSA aggregates by DLS 
Furthermore, the HSA aggregates formed at 65 °C, when analyzed by dynamic light 
scattering, as expected, showed polydispersity with hydrodynamic radii of ~ 156 ± 21 
nm, thereby supporting an amyloid, rather than just oligomeric, nature of the aggregates 
(Figure 38B). Measurements were carried out using 1 ml quartz cuvette with the sample 
chamber pre-maintained at 25 °C. The samples were illuminated with a 658 nm laser light 
and scattering intensity were measured at 165° angle. From the number distribution of the 
molecular species from DLS data, the mean hydrodynamic radii obtained for the samples 
were: HSA monomer: 3.2 ±	0.9 nm (polydispersity: 18 %); HSA amyloid aggregates: 
156 ±	21 nm (polydispersity: 30 %). The buffers used for these samples were: HSA 
monomer: 50 mM glycine-HCl+50 mM NaCl, pH 3.0, 8 M urea; HSA amyloid 
aggregates: 10 mM sodium phosphate + 50 mM NaCl, pH 7.4 (Figure 38A and 38B). 
 
             Figure 38. Estimation of molecular sizes of HSA aggreaggtes by DLS 
Dynamic light scattering measurements were carried out on 
HSA monomer (A) and HSA amyloid aggregates which are 
formed by incubation at 65 °C for 52 hrs (B). 
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4.3.4 Transmission electron microscopy of HSA aggregates 
When analyzed by TEM, the HSA aggregates formed at 65 °C showed elongated fibrillar 
morphologies as reported previously thereby confirming their amyloid nature [71] 
(Figure 39A-D). 
 
       Figure 39. Morphologies of HSA amyloid aggregates viewed in TEM 
(A-D) TEM images of negatively stained HSA amyloid 
aggregates, obtained by incubation at 65°C for 52 hrs at pH 7.4, 
that were used for sarkosyl stability assay and as pre-formed 
seed in subsequent experiments. 
 
4.3.5 Evaluation of HSA aggregates as true amyloid 
4.3.5.1 Semi denaturing detergent agarose gel electrophoresis (SDD-AGE) 
Protein amyloid aggregates show increased stability against denaturants (e.g. urea) and 
ionic detergents (e.g. SDS and sarkosyl) when compared with amorphous aggregates [23]. 
Assay was performed to examine the stability of HSA aggregates against ionic detergent 
sarkosyl (2 %) using SDD-AGE (Figure 40), HSA aggregates exhibited higher molecular 
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weight species upon incubation with 2 % sarkosyl at room temperature, indicating their 
resistance against dis-aggregation. Using calibration curve generated by relative mobility 
of proteins of known molecular weight, it was estimated that the sarkosyl-stable species 
of HSA amyloid aggregates were over 6084 kDa in size and thus composed of over 90 
monomers. The observed sarkosyl stability strongly supports amyloid nature of HSA 
aggregates. 
 
Figure 40. Amyloid-like detergent stability of HSA aggregates 
Stability of HSA aggregates against 2 % sarkosyl was assessed by using 
SDD-AGE. Samples were incubated with 2% sarkosyl at room temperature 
for 10 minutes and electrophoresed on 1.5 % agarose gel followed by 
electroblotting to PVDF membrane and visualized by Coommassie staining. 
High molecular weight smear of HSA aggregates (Lane 2) is shown relative 
to the stained HSA and BSA monomers. A mixture of HEWL, BSA 
monomer and BSA homodimer were used as markers. Lane 1: HSA 
monomer; Lane 2: HSA aggregates; Lane 3: BSA monomer; Lane 4: BSA 
amyloid aggregates, Lane 5: mixture of HEWL, BSA monomer & BSA 
homodimer. 
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4.3.5.2 Assay of seeding capability of HSA aggregates   
In addition to detergent stability, ability to self-seed aggregation of their monomers 
distinguishes amyloid aggregates from amorphous protein aggregates [5]. In order to 
visualize kinetics of seeding, a lag dependent growth of the amyloid is a pre-requisite. 
For many amyloidogenic proteins, addition of pre-formed seed completely eliminates 
the lag phase whereas, for others such as the human TDP-43 protein implicated in 
Amyotrophic Lateral Sclerosis, seeding manifests as reduction in the lag period [103]. 
Previously, it has been shown that HSA amyloid aggregation proceeds without any lag 
phase at 65 °C [72]. Therefore, self-seeding ability of pre-formed HSA aggregates could 
not be monitored at the optimal 65°C temperature. Thus, we examined a suboptimal 
aggregation temperature (50°C) where spontaneous aggregation of HSA would be 
expectedly negative due to lack of successful oligomeric nuclei formation, that normally 
precedes amyloid aggregation [2]. However, the added pre-formed seeds which contain 
pre-formed nuclei may initiate the conversion of monomers to aggregates and show the 
seeding kinetics even at suboptimal aggregation temperatures.  
 
Figure 41. Amyloid-like self-seeding of HSA aggregates 
Pre-formed HSA aggregates (as 5% seed) were added to monomeric 
HSA (20 mg/ml) dissolved in aggregation buffer of pH 7.4 
containing 2 mM ThT. Mixture was incubated at 50°C for 96 hrs 
without agitation in Spectramax- M5e microplate reader. ThT 
fluorescence emission intensities were recorded every 5 min. 
Aggregation kinetics of HSA monomer without pre-formed seed 
was used as a control. 
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Similar strategy has been used to demonstrate self-seeding of TDP-43 amyloid at 
suboptimal aggregation conditions, where the sample were kept at static, in the view that 
shaking causes aggregation of TDP-43 without a lag phase [103]. Indeed, as per our 
hypothesis, the HSA amyloid aggregates showed self-seeding at 50°C as observed by 
amyloid-like increase in ThT fluorescence intensity (Figure 41) [7]. Notably, the self-
seeding of the HSA aggregation was observed to reduce the lag phase but not completely 
abrogate it. 
4.3.5.3 TEM of self-seeded HSA aggregates 
HSA aggregates obtained at 50 °C by seeding with pre-formed aggregates also showed 
fibrillar amyloid-like structures as observed by TEM, thereby supporting the process of 
HSA amyloid self-seeding (Figure 42 A-D).  
 
Figure 42. Morphologies of HSA amyloid aggregates obtained upon seeded aggregation 
(A-D) TEM images of HSA amyloid aggregates which were previously obtained 
by incubation at 50 °C by seeded aggregation were acquired by TEM (T20G2) 
operated at 200 kV. A drop of the aggregates suspension was placed on a carbon-
coated copper grid, dried in desiccator and negatively stained with 0.2 % 
Phosphotungstic acid (PTA) for 2 minutes, before imaging. 
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4.3.5.4 Cross-seeding of HSA and BSA aggregates 
Amyloid cross-seeding between prion form of bovine PrPSc protein and the human soluble 
PrPC protein, is proposed as the basis of species-barrier crossing of prion transmission, 
which is yet to be proven beyond doubt [24,95,104]. Bovine and human prion proteins 
causing Bovine spongiform encephalopathy and Creutzfeldt-Jakob disease have been 
known to have biochemical and pathological similarities [24]. In this line, we examined 
whether bovine serum albumin (BSA) and HSA amyloid can show cross-seeding in the 
view that HSA and BSA proteins share over 76 % sequence similarity [105].  
Monomeric HSA (10 mg/ml) was incubated with sonicated, pre-formed BSA aggregates 
(as 5 % seed) at 50 °C in 10 mM sodium phosphate buffer, pH 7.4 containing 50 mM 
NaCl in presence of ThT. Gradual, sigmoidal increase in ThT fluorescence intensity was 
observed with time suggesting possibility of amyloid-like cross-seeding of HSA 
aggregates (Figure 43A). Similar trend was also found when monomeric BSA was 
incubated with pre-formed HSA aggregates (5 % seed) (Figure 43B). If pre-formed HSA 
and BSA aggregates are successfully able to cross-seed each other’s aggregation, they 
may act as good candidates for amyloid cross-seeding mechanism investigations. Study of 
their cross-seeding ability may serve as a possible model for species barrier cross-seeding of 
amyloid aggregates. 
 
Figure 43. Cross-seeding kinetics of HSA and BSA aggregation  
(A) Solid line represents HSA cross-seeded by pre-formed BSA aggregates (5% 
seed) and dashed line represent unseeded HSA. (B) BSA cross-seeded by pre-formed 
HSA aggregates (solid line). Dashed line indicate unseeded BSA.  
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4.3.6 HSA homo-dimerization and purification 
4.3.6.1 Estimation of free sulfhydryl group in HSA by Ellman’s method 
5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB) also known as Ellman’s reagent was used to 
determine the number of free sulfhydryl group in HSA [106]. Sulfhydryl groups may be 
quantitated by using the extinction coefficient of TNB released upon reaction with DTNB. 
Protein samples of BSA, HSA or lysozyme at 0.15 mM concentration were mixed with 
DTNB (4 mg/ml) in the reaction buffer (sodium phosphate buffer pH 8.0) and incubated 
for 15 minutes at room temperature and absorption was measured at 412 nm. 
Subsequently, free –SH group content was calculated using the following equation. The 
reported molar absorptivity of TNB in this buffer system at 412 nm is 14,150. Molar 
absorptivity, Ε, is defined as follows:  
E=A/bc 
(where, A = absorbance, b = path length in cm, c = concentration in moles/liter)  
Solving for concentration gives the following formula: c=A/bE.  
 
Table 5. Estimation of free cysteine in HSA by Ellman’s reagent assay 
Concentration 
of the sample 
Estimated no. of free 
– SH group/molecule 
Reported no. of free 
– SH group/molecule 
HSA (0.10 mM) [Ref. 61] 1.0 1.0 
β- mercaptoethanol (0.25 mM) 1.1 1.0 
BSA (0.15 mM) [Ref.105] 0.5 0.5 
Lysozyme (0.07 mM) [Ref.106] 0.1 0.0 
 
In order to dimerize HSA molecules via disulfide linkage, the availability of one free 
cysteine residue needed to be confirmed. This estimation of the free cysteine was carried 
out using Ellman’s reagent assay (Table 5) [106]. Free cysteine estimation was also carried 
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out for BSA, β-mercaptoethanol and Hen Egg White Lysozyme for comparison and 
validation of the estimation [63,107,108].   
4.3.6.2 H2O2 induced disulfide-linked homo-dimerization of HSA  
With the goal of examining whether homodimer of HSA which finds several clinical 
applications retains amyloidogenicity, we first tried to dimerize HSA via its cysteine-34 
residues. Conjugation of two HSA monomers via their free cysteine-34 was carried out in 
presence of 8 M urea and 25 mM/100 mM H2O2.  Urea (8 M) was used for exposing out 
the one free cysteine-34, which is present in a 10 Å deep crevice in the native molecule 
[109]. Unfolding of HSA in 8 M urea, has already been shown to be reversible [110]. 
Optimal H2O2 concentration required for dimerization was found to be 25 mM and any 
further increase, even to 100 mM, did not elevate the levels of dimer formation. As shown 
in Figure 44 (lane 4 and 6) the ratio of dimer to monomer molecules in presence of 25 mM 
H2O2  was ~ 2 : 3 as estimated by Image J densitometry software [111]. Formation of very 
little dimer population as seen in lanes 2 & 8 of Figure 43 support that presence of both 
urea and H2O2 together, are necessary for efficient dimerization. 
 
 
 Figure 44. Hydrogen peroxide induced dimerization of HSA. 
HSA homodimer formation was monitored on 10% SDS-PAGE under reducing (R) and 
non-reducing (NR) conditions. HSA+ 8 M urea (R): Lane A & Lane 1; HSA+ 8 M urea 
(NR): Lane B & Lane 2; HSA+8 M Urea+25 mM H2O2: Lane 3 (R) and Lane 4 (NR); 
HSA+8 M Urea+100mM H2O2: Lane 5 (R) and Lane 6 (NR); HSA+ 100 mM H2O2: 
Lane 7 (R) and Lane 8 (NR). Comparison of lane 4 and 6 shows that presence of H2O2 
and urea together is essential for efficient dimerization of HSA. Relative intensity of 
HSA dimer and HSA monomer bands were estimated by using Image J software [111].  
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4.3.6.3 Size exclusion chromatography 
4.3.6.3.1 Separation of HSA monomers and dimers by gel filtration using FPLC  
As the dimerization of HSA was not a 100% efficient process, thus the dimers needed to 
be separated out from monomers. The HSA dimers were purified from the mixture of 
monomers based on the differences in their molecular weights, by SEC using Superose 
6 column on FPLC (Figure 44A). As expected, two peaks were obtained in the elution 
profile, the first peak fractions contained predominantly dimer molecules while the 
second peak fractions showed mostly monomers (Figure 45A and 45B). The fractions 
containing predominantly HSA dimers were pooled and further analyzed for amyloid 
forming ability under conditions as described for HSA monomer. 
 
Figure 45. Purification of HSA dimer by size exclusion chromatography 
(A) Elution profile showing separation of HSA dimer (peak-I) and HSA monomer 
(peak-II) by size exclusion chromatography on Superose 6, 10/300 GL column using 
ÄKTA™ FPLC system. (B) Homogeneity of the purified fractions from FPLC was 
assessed by 10% SDS-PAGE. Lanes 1, 2, 3 & 4 from peak-I in (A) were pooled as 
dimer fractions and lanes 7, 8, 9 &10 from peak-II in (A) were pooled as monomer 
fractions. 
 
4.3.6.3.2 Estimation of hydrodynamic radius of purified HSA dimer by DLS 
From the number distribution of the molecular species from DLS data, the mean 
hydrodynamic radii obtained for the samples were: HSA monomer: 3.2 ±	0.9 nm 
(polydispersity: 18 %); Purified HSA dimer: 6.7 ±	1.3 nm (polydispersity: 20 %) (Figure 
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46). The buffers used for these samples were: HSA monomer: 50 mM glycine-HCl+50 
mM NaCl, pH 3.0, 8 M urea; HSA dimer: 10 mM sodium phosphate + 50 mM NaCl, pH 
7.4, 8 M urea. 
 
Figure 46. Comparison of hydrodynamic radius of HSA monomer (A) and 
purified HSA dimer (B) using DLS. 
Scattering measurements were carried out on HSA monomer (A) which 
was compared with the DLS data for purified HSA homo-dimer (B). 
Samples were at final concentration of 5 mg/ml. Measurements were 
carried out at room temperature using Delsa Nano C Particle Analyzer 
(Beckman Coulter) and data were processed using Delsa Nano 3.7 
software. The samples were illuminated with a 658 nm laser light and 
scattering intensity were measured at 165° angle. 
 
4.3.6.3.3 Stability of HSA homodimer to mild reducing agent  
The formed HSA homodimer was examined for its stability to mild reducing agent DTT 
(2.5 mM). Assessment of stability of HSA homodimer to reducing condition is important 
for better applicability, in the view that HSA drug formulations could be administered 
through injection in blood which may carry mild reducing agents. Also, if applied for 
drug delivery to tumors where microenvironment may be reducing, it may lead to 
breakdown of dimer to monomer. HSA homo-dimerization mixture is incubated with 
sample buffer containing 2.5 mM DTT and examined for stability by SDS-PAGE. Same 
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sample was also loaded in presence of reducing sample buffer and completely non-
reducing sample buffer for comparison. We observed that the presence of mild reducing 
agent does not have any effect on HSA homodimer as the sample is quite comparable to 
the sample in presence of non-reducing sample buffer (Figure 47). 
 
 
Figure 47. Assessment of stability of HSA homodimer 
 to reducing agent by SDS-PAGE. 
 Lane 2: HSA homo-dimerization mixture 
(reducing condition, 100 mM DTT; Lane 3: HSA 
homo dimerization mixture (non-reducing 
condition);   Lane 4: HSA homo-dimerization 
mixture (reducing condition with 2.5 mM DTT). 
 
4.3.7 In vitro amyloid-like aggregation of HSA homodimer 
4.3.7.1 ThT and Congo red binding assays 
The HSA dimers were found to aggregate and exhibit amyloid-like ThT fluorescence 
emission and excitation similar to HSA monomer aggregates (Figure 48A and 48B) 
[7]. Also, when added with Congo red, the dimer aggregates caused red shift in Congo 
red absorption maximum from 480 nm to 540 nm accompanied by increase in 
absorption intensity near 540 nm suggesting amyloid-like nature of the aggregates 
(Figure 49) [88]. 
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Figure 48. Assessment of amyloid nature of HSA dimer aggregates 
(A) HSA dimers (20 mg/ml) were incubated in aggregation buffer 10 mM sodium 
phosphate, pH 7.4, with 50 mM NaCl at 65°C for 52 hrs. ThT fluorescence emission 
spectrum of HSA dimer aggregates (solid line) added with 2 mM ThT, was recorded by 
excitation at 442 nm. (B) ThT fluorescence excitation spectra of aggregates of HSA 
dimers (solid line), were recorded from 250-455 nm using emission at 495 nm. In both 
cases (A & B) the dashed line represents buffer control spectrum. 
 
 
 
 Figure 49. Assessment of Congo red binding of HSA dimer aggregates 
HSA dimer aggregates (solid line) or HSA monomer aggregates (dotted line) 
(10 mg/ml) were mixed with Congo red in 1:1 molar ratio and Congo red 
binding was assessed by recording absorption spectra from 300-700 nm and 
compared with that of HSA monomer aggregates (dotted line). Absorption 
wavelength maximum shift from 480 nm to 540 nm, indicates presence of 
amyloid. The dashed line represents buffer control spectrum. 
 
 80 
 
 
4.3.7.2 Atomic Force Microscopy (AFM) of HSA dimer aggregates 
Amyloid fibrils are highly ordered fibrillar structures. Atomic force microscopy (AFM) 
is one of the most widely used techniques to study the structural properties of amyloid 
fibrils. Some of the advantages of AFM for amyloid observation includes relatively easier 
sample preparation and avoidance of any unwanted structural changes to amyloid 
aggregate samples [112]. Amyloid-like fibrillar morphology of the HSA dimer aggregates 
was ascertained by AFM imaging which showed presence of elongated curly fibers of 
height ranging from ~ 15 to 20 nm (Figure 50). Similar morphologies of HSA amyloid 
aggregates have also been reported elsewhere [113].  
 
                    Figure 50. AFM imaging of HSA dimer aggregates. 
HSA dimer aggregates formed after 52 hrs of incubation 
at 65 °C. Before imaging, the sample was diluted 30 folds 
in aggregation buffer and drop casted on freshly cleaved 
mica sheet and dried. Typical fibrillar amyloid aggregates 
have been arrow-marked. 
 
4.4 Materials and Methods 
4.4.1 Materials 
Recombinant HSA expressed in Saccharomyces cerevisiae, Congo red, Thioflavin-T, N-
Lauroylsarcosine sodium salt (Sarkosyl), Sodium dodecyl sulphate (SDS), Hydrogen 
peroxide, 5, 5’-Dithio-bis (2-Nitrobenzoic acid) (DTNB, Ellman’s reagent) and dialysis 
membrane were purchased from Sigma-Aldrich, USA. Polyvinylidene fluoride 
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membrane (PVDF) and Superose 6, 10/300 GL high performance gel filtration column 
was obtained from GE Healthcare, USA. Urea, Sodium chloride, Sodium phosphate 
dibasic and monobasic were purchased from Himedia, India. All other chemicals were 
also of high purity. 
 
4.4.2 Amyloid aggregation and detection 
HSA protein was diluted in aggregation buffer (10 mM sodium phosphate buffer pH 7.4 
containing 50 mM NaCl) to a final concentration of 20 mg/ml and incubated without 
agitation at 65°C for 52 hrs in a water bath to induce aggregation as reported previously 
[71,72]. Amyloid aggregate formation was assessed by ThT and Congo red binding 
assays as described below.  
4.4.2.1 Thioflavin-T binding assay 
HSA aggregates (20 mg/ml) were mixed with ThT solution (2 mM final) and ThT 
fluorescence emission spectrum was monitored by excitation at 442 nm and recording 
emission from 460 nm to 560 nm. Excitation spectra of ThT, after addition to aggregates, 
was also recorded between 250-455 nm after fixing the emission to 495 nm [7].  
4.4.2.2 Congo red binding assay 
The dye Congo red can bind to amyloid aggregates with high specificity, which can 
manifest as a red shift in its absorption maximum (λmax) from 480 nm to 540 nm or 
increase in absorption intensity in 480-540 nm range [88]. To examine amyloid nature of 
HSA aggregates, Congo red dye was solubilized in phosphate buffered saline, pH 7.4 and 
then mixed with ~150 µM HSA aggregates in 1:1 molar ratio. The mixture was incubated 
for 30 min at room temperature and Congo red absorption was recorded from 300 nm to 
700 nm [88].  
4.4.3 Semi-denaturing detergent agarose gel electrophoresis (SDD-AGE) 
Several amyloid and prion aggregates have been shown to exhibit stability against dis-
aggregation by ionic detergents like SDS or sarkosyl (~1-2 %), when tested at room 
temperature [10,23,92]. Amyloid-like detergent stability of the HSA aggregates was 
 82 
 
 
examined by SDD-AGE [91]. Briefly, the HSA aggregates were first incubated with 2 % 
sarkosyl at room temperature for 10 min and then mixed with non-reducing Laemmli 
sample buffer lacking detergent and electrophoresed on 1.5 % agarose gel. Protein from 
the gel was electro-blotted to PVDF membrane and visualized by Coommassie staining 
[78,91]. 
4.4.4 Amyloid seeding assay 
Many amyloid aggregates exhibit lag depended sigmoidal kinetics of formation [5]. Upon 
addition of pre-formed aggregates (seed), the lag in aggregation can either shorten or 
completely disappear due to a process termed ‘self-seeding’, where the monomers are 
induced to aggregate with rapidity by the seed [103,114]. To confirm ordered amyloid 
structure and distinguish it from randomly misfolded amorphous aggregates which cannot 
show seeding ability. The formed amyloid aggregates of HSA were subjected to self-
seeding analysis (Figure 51). HSA aggregates (5%) pre-formed at 65°C were briefly 
sonicated to break the clumps and added to monomeric HSA (20 mg/ml) dissolved in 
aggregation buffer of pH 7.4 containing 2 mM ThT. Sonication breaks the large amyloid 
aggregates into smaller seeds with suitable ends for amyloid growth. This mixture was 
then incubated with intermittent shaking at 50°C for 96 hrs in Spectramax- M5e 
multimode microplate reader (Molecular Devices) and amyloid conversion of the 
monomer was monitored by recording ThT fluorescence. Aggregation kinetics of an HSA 
sample incubated without any pre-formed seed was used for comparison. A sample 
containing only the 5 % sonicated seed and lacking any HSA monomer was used as a 
control.  
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Figure 51. Steps for self-seeding aggregation assay of HSA  
 
4.4.5 Transmission Electron Microscopy 
The electron micrographs of HSA aggregates were acquired using a high-resolution 
transmission electron microscope (FEI Tecnai, T20G2), operated at 200 kV. TEM 
imaging was carried out by following same method as described in before in materials 
and methods section of chapter III. 
4.4.6 Atomic Force Microscopy  
Atomic force microscopy (AFM) of HSA aggregates obtained from cysteine-linked homo 
dimers was performed by drop-casting 30-fold diluted aggregates on a freshly cleaved 
mica sheet. Multimode scanning probe microscope from Veeco Instrument Inc., USA 
equipped with a Nanoscope IV controller and AFM probe model - Tap190Al ( tip radius: ~ 10 nm, & tip height: 17 μm ) purchased from Budget Sensors, were used in tapping-
mode at ambient conditions to scan the sample. The cantilever had a resonant frequency 
of ca. 162 kHz and nominal spring constant of ca. 48 N/m with a 30 nm thick aluminium 
reflex coating on the back side of the cantilever of the length 225 μm. Imaging was carried 
out at a rate of 1 Hz and at a resolution of 512 × 512 pixels. 
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4.4.7 Dynamic Light Scattering 
Dynamic Light Scattering was recorded using Delsa Nano C Particle Analyzer (Beckman 
Coulter) and data were processed using Delsa Nano 3.7 software. DLS measurements 
were carried out similar to as described before in chapter III.  
4.4.8  HSA homo-dimerization and purification  
4.4.8.1 H2O2 induced disulfide-linked homo-dimerization of HSA  
HSA molecule has one free cysteine-34, which is reported to be buried in a cleft of ~10 Å 
[109]. We first confirmed the presence and accessibility of free cysteine by Ellman’s 
method using DTNB reagent (Table 5) [106]. H2O2 was used as an oxidizing agent for 
converting two free sulfhydryl groups (–SH) into a disulfide bond. HSA (150 µM) was pre-
incubated in 8 M urea to increase accessibility of the –SH groups and then mixed with 10 
mM, 25 mM or 100 mM H2O2  in reaction buffer (50 mM glycine-HCl pH 3.0 containing 
50 mM NaCl) and incubated at room temperature for 30 minutes. Formation of homodimer 
was assessed by SDS-PAGE under non-reducing conditions. Samples electrophoresed with 
reducing sample buffer were used to examine whether the dimers were indeed disulfide 
linked.  
4.4.8.2 Size-exclusion chromatography  
As the efficacy of H2O2 induced dimerization of HSA was not 100%, the dimers needed 
to be purified from the monomers. As the dimers and monomers differ by 66 kDa, thus 
we attempted separation using size-exclusion chromatography (SEC) on Superose 6, 
10/300 GL column with exclusion limit of 4x107 using FPLC (ÄKTA™ FPLC™, GE) 
system. Briefly, 400µl of HSA dimerization mixture was dialyzed using membrane of 25 
kDa mol. wt. cut-off to remove the urea and H2O2.  Dialyzed sample containing the mixture 
of monomer and dimer (10 mg/ml) was loaded on to the SEC column pre-equilibrated 
with loading buffer (50 mM Glycine-HCl pH 3.0 with 150 mM NaCl) and the protein was 
eluted using the same buffer. Fractions of 0.25 ml volume were collected and elution of 
the protein was profiled using the UV detector of the FPLC by absorbance at 280 nm. 
Purity of fractions was assessed by SDS-PAGE using non-reducing sample buffer. 
Fractions containing HSA dimers, were pooled and ammonium sulfate precipitated to 
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concentrate the protein. The pelleted protein was dissolved in aggregation buffer and 
examined for amyloid aggregation using the method described above for HSA monomers. 
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Chapter V 
 
Conclusions  
 
 
Protein misfolding has been shown to lead to several devastating diseases such as 
Alzheimer’s, Parkinson’s, Creutzfeldt–Jakob disease and Prion diseases etc. Several non-
disease causing proteins like Human serum albumin can also form amyloid. 
Aggregation of human Seminogelin-1 protein is implicated in development of SSVA 
disorder.  The first part of this thesis describes were the cloning, expression and 
purification of recombinant human Sg1 and Sg1 (1-159) using E. coli and also their 
characterization. These purified proteins were further utilized for study of their amyloid 
forming capability. 
The thesis explores new insights into amyloid-like aggregation of human proteins Sg1 
and HSA, the most abundant proteins in seminal plasma and blood plasma respectively. 
This is the first study to investigate the amyloid forming ability of Sg1 full length protein 
in vitro. So far, only small peptides of Sg1 have been demonstrated to be amyloidogenic 
in vitro. We succeeded in obtaining aggregates of Sg1 and Sg1 (1-159) which manifested 
amyloid-like binding to Thioflavin-T and Congo red dyes and also followed lag-
dependent sigmoidal growth pattern and beta-sheet rich conformation, as observed 
previously for several amyloids. Furthermore, these aggregates also exhibited amyloid-
like stabilities to ionic detergents: SDS & Sarkosyl. Also showed partial resistance to 
Proteinase-K digestion. In addition, dynamic light scattering results estimated presence 
of  > 400 nm size particles in both Sg1 and Sg1(1-159) aggregates, as expected of 
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amyloid-like aggregates. The data showed that Sg1 and its fragment Sg1 (1-159) form 
amyloid-like aggregates in vitro. It is known that, seminal levels of Zinc, which is known 
to bind to Sg1 in vivo and is essential for health of male reproductive system, gradually 
decline with age [54,55]. Notably, presence of Zn2+ substantially inhibited the in vitro 
aggregations of Sg1 and Sg1 (1-159) proteins, a finding that may have relevance to 
understanding of the development of SSVA. The results might help to develop amyloid 
inhibitors. 
The later part of the study demonstrates new features of amyloid-like aggregation of HSA. 
Here, it is observed that HSA aggregates display true amyloid characteristics of self-
seeding and detergent stability. The findings here that HSA aggregates are stable to 
sarkosyl at room temperature, strongly advocate their amyloid-like nature. A signature of 
amyloid aggregates is self-seeding ability wherein they coax the monomers to misfold 
and join the aggregates, thus if HSA aggregates were true amyloid displaying self-seeding 
would be imperative. Furthermore, if found to be self-seeding precautions to prevent any 
amyloid contamination in drug formulations containing HSA would become essential. 
Especially in the view that encapsulation of drugs by HSA as well as amyloid formation 
by HSA are frequently obtained at elevated temperatures [71,115]. By assessing the 
seeding kinetics at suboptimal conditions, we found that HSA aggregates can indeed 
show self-seeding feature. Although, HSA has not been shown to aggregate in vivo, 
seeding by amyloid contamination from drugs may become an inducing risk factor for 
initiating in vivo HSA aggregation. It is known that amyloid  aggregate contamination of 
prion protein PrPSc  from surgery or infected food sources can start in vivo conversion of 
monomeric PrPC into aggregated PrPSc causing Creutzfeldt Jacob disease [6,24]. We also 
succeeded, in obtaining disulfide linked dimers of HSA, without employing any cross-
linking agent. These dimers being free of any immunogenic cross-linking agent may be 
preferable for therapeutic applications over conventional HSA dimers obtained via 
chemical cross-linking. As HSA dimers are widely considered as better drug carriers than 
monomers, we examined whether dimers are also capable of amyloid aggregation. 
Indeed, we found that HSA dimers also possess amyloid forming capabilities alike the 
monomers. This further necessitates precautionary considerations. 
 88 
 
 
The results presented in this thesis can have some possible future implications and can 
potentiate future research directions. For example, Sg1 full length and Sg1 (1-159) 
amyloids can in future be used to examine whether they can also enhance HIV infectivity 
similar to the amyloid of small Sg1 peptides.  Observed Sg1 amyloid Inhibition by Zn2+ 
could be examined to develop preventive or therapeutic strategies for SSVA. Self-seeding 
ability of HSA aggregates suggests need for precautions. Protein misfolding cyclic 
amplification (PMCA) like techniques can be considered for possible screening for 
presence of any amyloid in HSA drug formulations. Observed cross-seeding between 
HSA and BSA could be explored in detail and can serve as a possible model for 
examining species barrier crossing of amyloid and prion propagation or infection. 
Obtained HSA homodimer without chemical cross-linker, being non-immunogenic, may 
be preferable over conventional HSA dimers containing chemical cross-linker for 
therapeutic applications such as a plasma expander or a drug carrier. 
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